id,summary
0,"[/INST]C0C0C0C0C0C0000000000000000000C000000C0AC00000000000- aB0000000000000000000000X0X0C-,C0C0C0C0C0C0C000000000000000000000000000000000000000000C0C000000000000000000000-,', a000000000- 1C000000000-aC00000000000000000000000000000000000- 0- 10- 1- 0- 0- 1- ', a- 0- a0- 0- a- ', a- ', ', ', ', o- ', ', ', 1- 1- ', ',- 0- -,- ',-a-a- ', ', 1- 1- 1- ', ', ', ', ', ', ', ', 1- 1- 1- ', ', ', ', ', ', -', - ', ', ', ', a- ', a- ', ', ', ', ', ', ', 1000000000rdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrd0000000- 1- 1- 10- ', a- ', 1000000000rdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrd"
1,"[/INST]

Pressure Ulcer Risk Assessment
-----------------
| Examine the patient's medical history for pressure sores. | Look for signs of unstable pressure. | Assess the patient's ability to tolerate a sitting position using the block system from the bed. | Determine the patient's ability to ambulate using the cube/block system from the bed. | Examine the patient's ability to tolerate a sitting position using the massage mattress with a cube/block system. | Assess the patient's ability to tolerate a sitting position using the cube/block system from the bed. |

Comparison of the Pressure Ulcer Risk Assessment Tools
-----------------
| Examine the patient's medical history for pressure sores. | Look for signs of instability in the patient's ability to tolerate a sitting position using the massage mattress with a cube/block system from the bed. | Assess the patient's ability to ambulate using the cube/block system from the bed. | Determine the patient's ability to tolerate a sitting position using the massage mattress with a cube/block system from the bed. | Examine the patient's medical history for pressure sores. |

Comparison of the Pressure Ulcer Risk Assessment Tools
-----------------
| Examine the patient's medical history for pressure sores. | Look for signs of instability in the patient's ability to tolerate a sitting position using the massage mattress with a cube/block system from the bed. | Assess the patient's ability to ambulate using the cube/block system from the bed. | Determine the patient's medical history for pressure sores. | Examine the patient's ability to tolerate a sitting position using the massage mattress with a cube/block system from the bed. |

Comparison of the Pressure Ulcer Risk Assessment Tools
-----------------
| Examine the patient's medical history for pressure sores. | Look for signs of instability in the patient's ability to tolerate a sitting position using the massage mattress with a cube/block system from the bed. | Assess the patient's medical history for pressure sores. | Determine the patient's ability to"
2,"[/INST]
Other: [Pediatric] Diabetes, [Treatment/Intervention], Quality of Life, Augmented Reality Glasses, [Treatment/Intervention], Anthropometric Values, [Treatment/Intervention], Quality of Life, [Treatment/Intervention], Augmented Reality Glasses, [Treatment/Intervention], Anthropometric Values, [Treatment/Intervention], Quality of Life, [Treatment/Intervention], Augmented Reality Glasses, [Treatment/Intervention], Quality of Life, [Treatment/Intervention], Augmented Reality Glasses, [Treatment/Intervention], Quality of Life, [Treatment/Intervention], Augmented Reality Glasses, [Treatment/Intervention], Quality of Life, [Treatment/Intervention], Augmented Reality Glasses, [Treatment/Intervention], Quality of Life, [Treatment/Intervention], Augmented Reality Glasses, [Treatment/Intervention], Quality of Life, [Treatment/Intervention], Augmented Reality Glasses, [Treatment/Intervention], Quality of Life, [Treatment/Intervention], Augmented Reality Glasses, [Treatment/Intervention], Quality of Life, [Treatment/Intervention], Augmented Reality Glasses, [Treatment/Intervention], Quality of Life, [Treatment/Intervention], Augmented Reality Glasses, [Treatment/Intervention], Quality of Life, [Treatment/Intervention], Augmented Reality Glasses, [Treatment/Intervention], Quality of Life, [Treatment/Intervention], Augmented Reality Glasses, [Treatment/Intervention], Quality of Life, [Treatment/Intervention], Augmented Reality Glasses, [Treatment/Intervention, Quality of Life, [Treatment/Intervention, Augmented Reality Glass"
3,"[/INST]
Virtual reality (VR) is an interactive three-dimensional image or hologram, which can be experienced by a person wearing special glasses.
Virtual reality (VR) is an interactive three-dimensional image or hologram, which can be experienced by a person wearing special glasses.
Primary Outcome Measure: Anxiety level measured by VAS-A scale before and after watching virtual reality with smart bracelet.
Secondary Outcome Measure: Watching video with virtual reality glasses.
Virtual reality (VR) is an interactive three-dimensional image or hologram, which can be experienced by a person wearing special glasses.
Primary Outcome Measure: Anxiety level measured by VAS-A scale before and after watching video with virtual reality glasses.
Secondary Outcome Measure: Watching video with virtual reality glasses.
Virtual reality (VR) is an interactive three-dimensional image or hologram, which can be experienced by a person wearing special glasses.
Primary Outcome Measure: Anxiety level measured by VAS-A scale before and after watching video with virtual reality glasses.
Secondary Outcome Measure: Watching video with virtual reality glasses.
Virtual reality (VR) is an interactive three-dimensional image or hologram, which can be experienced by a person wearing special glasses.
Primary Outcome Measure: Anxiety level measured by VAS-A scale before and after watching video with virtual reality glasses.
Secondary Outcome Measure: Watching video with virtual reality glasses.
Primary Outcome Measure: Anxiety level measured by VAS-A scale before and after watching video with virtual reality glasses.
Virtual reality (VR) is an interactive three-dimensional image or hologram, which can be experienced by a person wearing special glasses.
Primary Outcome Measure: Anxiety level measured by VAS-A scale before and after watching video with virtual reality glasses.
Secondary Outcome Measure: Watching video with virtual reality glasses.
Primary Outcome Measure: Anxiety level before and after watching video with virtual reality.
Primary Outcome: Anxiety level measured by VAS the intervention with virtual reality glasses.
Primary Outcome Measure: Anxiety level measured by VAS the intervention"
4,"[/INST]

How is the study designed?
| Designed by: [/INST]

How is the study conducted?
| Conducted by: [/INST]

How is the study organized?
| Organized by: [/INST]

How is the study structured?
| Structured by: [/INST]

How is the study organized?
| Organized by: [/INST]

How is the study presented?
| Presented by: [/INST]

How is the study presented?
| Presented by: [/INST]

How is the study structured?
| Structured by: [/INST]

How is the study structured?
| Structured by: [/INST]

How is the study structured?
| Structured by: [/INST]

How is the study structured?
| Structured by: [/INST]

How is the study structured?
| Structured by: [/INST]

How is the study structured?
| Structured by: [/INST]

How is the study structured?
| Structured by: [/INST]

How is the study structured?
| Structured by: [/INST]

How is the study structured?
| Structured by: [/INST]

How is the study structured?
| Structured by: [/INST]

How is the study structured?
| Structured by: [/INST]

How is the study structured?
| Structured by: [/INST]

How is the study structured?
| Structured by: [/INST]

How is the study structured?
| Structured by: [/INST]

How is the study structured?
| Structured by: [/INST]

How is the study structured?
| Structured by: [/INST]

How is the study structured?
| Structured by: [/INST]

How is the study structured?
| Structured by: [/INST]

How is the study structured?
| Structured by: [/INST]

How is the study structured?
| Structured by: [/INST]

How is"
5,"[/INST]
Other related Terms: [/INST]"
6,"[/INST]
Multiple Sclerosis, the Mediterranean Diet, and Quality of Life in MS patients.
Walking Impairment Scale: [/INST]
The 12-item MS Gait Scale will be used to determine the impact of walking in MS patients. The score given for each item is 0-10 points. A higher score indicates better gait impairment. | 12 months |
Quality of Life Scale: The 12-item MS Gait Scale will be used to determine the impact of walking in MS patients. The score given for each item is 0-10 points. A higher score indicates better gait impairment | 2 years |
Mediterranean Diet, and Quality of Life in MS patients.
Quality of Life Scale: The 12-item MS Gait Scale will be used to determine the impact of walking in MS patients. The score given for each item is 0-10 points. A higher score indicates better gait impairment. | 2 years"
7,"[/INST]
| Disease |
| Outcome: week 24 |
| Disease: week 24 |
| Outcome: week 24 |
| Disease: week 24 |
| Disease: week 24 |
| Outcome: week 24 |
| Disease: week 24 |
| Disease: week 24 |
| Outcome: week 24 |
| Disease: week 24 |
| Disease: week 24 |
| Outcome: week 24 |
| Disease: week 24 |
| Disease: week 24 |
| Outcome: week 24 |
| Disease: week 24 |
| Disease: week 24 |
| Outcome: week 24 |
| Disease: week 24 |
| Disease: week 24 |
| Outcome: week 24 |
| Disease: week 24 |
| Disease: week 24 |
| Outcome: week 24 |
| Disease: week 24 |
| Outcome: week 24 |
| Disease: week 24 |
| Outcome: week 24 |
| Disease: week 24 |
| Outcome: week 24 |
| Disease: week 24 |
| Outcome: week 24 |
| Disease: week 24 |
| Outcome: week 24 |
| Disease: week 24 |
| Outcome: week 24 |
| Disease: week 24 |
| Outcome: week 24 |
| Disease: week 24 |
| Outcome: week 24 |
| Disease: week 24 |
| Outcome: week 24 |
| Disease: week 24 |
| Outcome: week 24 |
| Disease: week 24 |
| Outcome: week 24 |
| Disease: week 24 |
| Outcome: week 24"
8,"[/INST]

| Other: Questionnaires |
| Botox |

| Overactive Bladder |
| Questionnaires |
| Discrete choice |

| Botox |

| Other: Questionnaires |
| Interventions |
| Discrete choice |

| Botox |

| Questionnaires |
| Other: Discrete choice |

| Botox |

| Questionnaires |
| Interventions |
| Discrete choice |

| Botox |

| Other: Questionnaires |
| Interventions |
| Discrete choice |

| Botox |

| Questionnaires |
| Interventions |
| Discrete choice |

| Botox |

| Other: Questionnaires |
| Interventions |
| Discrete choice |

| Botox |

| Questionnaires |
| Interventions |
| Discrete choice |

| Botox |

| Other: Questionnaires |
| Interventions |
| Discrete choice |

| Botox |

| Questionnaires |
| Interventions |
| Discrete choice |

| Botox |

| Other: Questionnaires |
| Interventions |
| Discrete choice |

| Botox |

| Questionnaires |
| Interventions |
| Discrete choice |

| Botox |

| Other: Questionnaires |
| Interventions |
| Discrete choice |

| Botox |

| Questionnaires |
| Interventions |
| Discrete choice |

| Botox |

| Other: Questionnaires |
| Interventions |
| Discrete choice |

| Botox |

| Questionnaires |
| Interventions |
| Discrete choice |
| Botox |

| Other: Questionnaires |
| Interventions |
| Discrete choice |
| Botox |

| Questionnaires |
| Interventions |
| Discrete choice |
| Botox |

| Other: Questionnaires |
| Interventions |
| Discrete choice |
| Botox |

| Questionnaires |
| Intervent"
9,"[/INST]..,........................................................................... B. B............................................... a. a. a. a. a. a a a a. a. a................. D. D. D. a H a H a B. a B. a. a. a. a. a. a. a a a a. a........................................ B................................ H. H. H H B H. H. H B H B H B H B H B. B H B H B H B H B H B....... B. B. B. B. B. a B a a a a a a a B. a B.
.
.
. B. H B H B H. H. H. H. H. H. H A H A H
.
.
.
.
.
.
.

























.
.


 H
 H
 H"
10,"[/INST]
Primary Outcome: [/INST]
Secondary Outcome: [/INST]
Treatment of [/INST]
Secondary Outcome: [/INST]
Other Outcome: [/INST]
Secondary Outcome: [/INST]
Primary Outcome: [/INST]
Secondary Outcome: [/INST]
Secondary Outcome: [/INST]
Secondary Outcome: [/INST]
Secondary Outcome: [/INST]
Secondary Outcome: [/INST]
Secondary Outcome: [/INST]
Secondary Outcome: [/INST]
Secondary Outcome: [/INST]
Secondary Outcome: [/INST]
Secondary Outcome: [/INST]
Secondary Outcome: [/INST]
Secondary Outcome: [/INST]
Secondary Outcome: [/INST]
Secondary Outcome: [/INST]
Secondary Outcome: [/INST]
Secondary Outcome: [/INST]
Secondary Outcome: [/INST]
Secondary Outcome: [/INST]
Secondary Outcome: [/INST]
Secondary Outcome: [/INST]
Secondary Outcome: [/INST]
Secondary Outcome: [/INST]
Secondary Outcome: [/INST]
Secondary Outcome: [/INST]
Secondary Outcome: [/INST]
Secondary Outcome: [/INST]
Secondary Outcome: [/INST]
Secondary Outcome: [/INST]
Secondary Outcome: [/INST]
Secondary Outcome: [/INST]
Secondary Outcome: [/INST]
Secondary Outcome: [/INST]
Secondary Outcome: [/INST]
Secondary Outcome: [/INST]
Secondary Outcome: [/INST]
Secondary Outcome: [/INST]
Secondary Outcome: [/INST]
Secondary Outcome: [/INST]
Secondary Outcome: [/INST]
Secondary Outcome: [/INST]
Secondary Outcome: [/INST]
Secondary Outcome: [/INST]
Secondary Outcome: [/INST]
Secondary Outcome: [/INST]
Secondary Outcome"
11,"[/INST]
| Group 3 |
| --- |
| Group 2 |
| --- |
| Group 1 |
| Group 2 |
| Group 3 |
| Group 4 |
| Group 5 |
| Group 6 |
| Group 7 |
| Group 8 |
| Group 9 |
| Group 10 |
| Group 11 |
| Group 12 |
| Group 13 |
| Group 14 |
| Group 15 |
| Group 16 |
| Group 17 |
| Group 18 |
| Group 19 |
| Group 20 |
| Group 21 |
| Group 22 |
| Group 23 |
| Group 24 |
| Group 25 |
| Group 26 |
| Group 27 |
| Group 28 |
| Group 29 |
| Group 30 |
| Group 31 |
| Group 32 |
| Group 33 |
| Group 34 |
| Group 35 |
| Group 36 |
| Group 37 |
| Group 38 |
| Group 39 |
| Group 40 |
| Group 41 |
| Group 42 |
| Group 43 |
| Group 44 |
| Group 45 |
| Group 46 |
| Group 47 |
| Group 48 |
| Group 49 |
| Group 50 |
| Group 51 |
| Group 52 |
| Group 53 |
| Group 54 |
| Group 55 |
| Group 56 |
| Group 57 |
| Group 58 |
| Group 59 |
| Group 60 |
| Group 61 |
| Group 62 |
| Group 63 |
| Group 64 |
| Group 65 |
| Group 66 |
| Group 67 |
| Group 68 |
| Group 69 |
| Group 70 |
| Group 71 |
| Group"
12,"[/INST]
























































A
A


A
A
A
A
A
A
A	A	A	A	A	A	A	A	A	A	A	A	-
A	A	A	A,
A	A	A
A
A
A
A
A
AAAAAAAAAAA	A	A	A"",A"",A"",A"",A"",A"",A	A	A	A					A	A	A	A	A		A	A	A	A	A	A	A	A	A	A	A	A	A	A		A	A	A	A										A	A	A		A	A																				A				A	A	A																																																																																																		1-a-a-a-a-a-a-a-a-a-a-a-a-a'- - - - - - - - - - - - - -a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a'- - - - -a'-auauuiveoiveo-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a'- - - - - - - - - - - - - - - - - -"
13,"[/INST]-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-C-
-C-
-
-C-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
--
-
-
-
---
--
----
-
-
-
-
-
-
----------------------------O------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------"
14,"[/INST]
Primary Outcome: Frequency of adverse events leading to permanent study discontinuation | Secondary Outcome: Change from baseline in vital signs over time | 
| Secondary Outcome: Percent change in vital signs over time | 
| Secondary Outcome: Change from baseline in vital signs over time | 
| Secondary Outcome: Percent change in vital signs over time | 
| Secondary Outcome: Change from baseline in vital signs over time | 
| Secondary Outcome: Percent change in vital signs over time | 
| Secondary Outcome: Percent change in vital signs over time | 
| Secondary Outcome: Percent change in vital signs over time | 
| Secondary Outcome: Percent change in vital signs over time | 
| Secondary Outcome: Percent change in vital signs over time | 
| Secondary Outcome: Percent change in vital signs over time | 
| Secondary Outcome: Percent change in vital signs over time | 
| Secondary Outcome: Percent change in vital signs over time | 
| Secondary Outcome: Percent change in vital signs over time | 
| Secondary Outcome: Percent change in vital signs over time | 
| Secondary Outcome: Percent change in vital signs over time | 
| Secondary Outcome: Percent change in vital signs over time | 
| Secondary Outcome: Percent change in vital signs over time | 
| Secondary Outcome: Percent change in vital signs over time | 
| Secondary Outcome: Percent change in vital signs over time | 
| Secondary Outcome: Percent change in vital signs over time | 
| Secondary Outcome: Percent change in vital signs over time | 
| Secondary Outcome: Percent change in vital signs over time | 
| Secondary Outcome: Percent change in vital signs over time | 
| Secondary Outcome: Percent change in vital signs over time | 
| Secondary Outcome: Percent change in vital signs over time | 
| Secondary Outcome: Percent change in vital signs over time | 
| Secondary Outcome: Percent change in vital signs over time | 
| Secondary Outcome: Percent change in vital signs over time |"
15,[/INST]
16,"[/INST]
The surgery.
The symptobe.
The symptine.
The sympt
It.
It.
It.
It.
It.
It.
It.
It
It
It
It
It
It
It
It
It
It
It
It
It.
It.
It.
It.
It.
It.
== a
== a
==>
==>
==>
==========>
==>
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
This
This
This
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
















==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
=="
17,"[/INST]

Other: [/INST]"
18,"[/INST]
| the mean body weight of 25 | Other: It is an observational study and no non-routine procedures will be performed on patients. | the mean body weight of 25 | Other: It is an observational study and no non-routine procedures will be performed on patients. | the mean body weight of 25 | Other: It is an observational study and no non-routine procedures will be performed on patients. | the mean body weight of 25 | Other: It is an observational study and no non-routine procedures will be performed on patients. |
| the mean body weight of 25 | Other: It is an observational study and no non-routine procedures will be performed on patients. |
| the mean body weight of 25 | Other: It is an observational study and no non-routine procedures will be performed on patients. |
| the mean body weight of 25 | Other: It is an observational study and no non-routine procedures will be performed on patients. |
| the mean body weight of 25 | Other: It is an observational study and no non-routine procedures will be performed on patients. |
| the mean body weight of 25 | Other: It is an observational study and no non-routine procedures will be performed on patients. |
| the mean body weight of 25 | Other: It is an observational study and no non-routine procedures will be performed on patients. |
| the mean body weight of 25 | Other: It is an observational study and no non-routine procedures will be performed on patients. |
| the mean body weight of 25 | Other: It is an observational study and no non-routine procedures will be performed on patients. |
| the mean body weight of 25 | Other: It is an observational study and no non-routine procedures will be performed on patients. |
| the mean body weight of 25 | Other: It is an observational study and no non-routine procedures will be performed on patients. |
| the mean body weight of 25 | Other: It is an observational study and no non-routine procedures will be performed on patients. |
| the mean body weight of 25 | Other: It is an observational study and no non-"
19,"[/INST]
The process.
The process.
The process.
The
The
This
In the
This
This
In the
In
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This   
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
S
S
S
S
S
This
This
This
This
This
This
This
This
This
This
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
This
This
This
S
S
S
S
S
S
S
S
This
This
This
This
This
This
This
S
S
S
S
S
S
This
This
This
This
This
This
This
S
S
S
S
S
S
S
S
S
This
This
This
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
This
This
This
S
S
S
S
S
S
S
S
S
F
This
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
C
C
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
be
be
be











S
S
S
S
S
S
S"
20,"[/INST]
| Experimental: Respiratory and neuromuscular function | 3 years |
| Other: Assessment Respiratory and neuromuscular function | 3 years |
| Experimental: Respiratory and neuromuscular function | 3 years |
| Other: Assessment Respiratory and neuromuscular function |
|
| Experimental: Respiratory and neuromusical function | 3 years |
| Other: Respiratory function |
| Experimental: Respiratory and neuromusical function | 3 years |
| Experimental: Respiratory function | Other: Respiron.
| Experimental: Respiron.
| Experimental: Respiron.
| 3 years.
| Experimental.
| 3 years.
| Experimental: Respilist's.
| Experimental: neuromat the hospital.
| Experimental:
| Experimental.
| Experimental.
| Experimental.
| Experimental.
| Experimental.
| Experimental.
| Experimental.
| Experimental.
| Experimental.
| Experimental.
| be| be| be|three experimental. Experimental.
|three.
|three.
|three.
|three. Experimental.
| three.
| three.
| three.
|three.
|three.
|three.
|three.
|three.
|three.
|three.
|three.
|three.
|three.
|three.
|three.
|three.
|three.
|three.
|three.
The hospital|three.
|three.
The team.
The team.
The team.
The team.
The team.
This|three.
The team.
The team.
The team.
The team.
The team.
The team.
The team.
The team.
The team.
The team.
The team.
The team.
The team.
The team.
The team.
The team.
The team.
The team.
The team.
The team.
The team.
The team.
The team.
The team.
The team.
The team"
21,"[/INST]
This
In
In
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
A
A
A
A
A




















This
This
This
This
This
This
This
A
g"
22,"[/INST]

Primary Purpose: To assess the safety and efficacy of ultra-hypofractionated radiotherapy in the treatment of early-stage breast cancer.
Secondary Purpose: To assess the safety and efficacy of partial breast irradiation in the treatment of early-stage breast cancer.
Partial breast irradiation is a minimally invasive form of breast cancer treatment that involves the use of radiation to treat early-stage breast cancer.
Early-stage breast cancer is a type of breast cancer that is detected at an early stage and is considered to be highly treatable with radiation therapy.
Radiation therapy involves the use of high-energy X-rays to kill cancer cells and shrink tumors.
Partial breast irradiation is a minimally invasive form of breast cancer treatment that involves the use of radiation to treat early-stage breast cancer and is considered to be highly effective in shrinking tumors.
Breast cancer is a type of cancer that begins in the breast tissue. It may also affect nearby lymph nodes and other parts of the body, including the lungs and liver.
Early-stage breast cancer is considered to be highly treatable with radiation therapy.
Radiation therapy involves the use of high-energy X-rays to kill cancer cells and shrink tumors.
Partial breast irradiation involves the use of radiation to treat early-stage breast cancer and may also be used to treat cancer that has spread to nearby lymph nodes.
Early-stage breast cancer is considered to be highly treatable with radiation therapy.
Radiation therapy may also be used in combination with other treatments, such as chemotherapy, hormone therapy, or surgery, depending on the individual case.
Radiation therapy involves the use of high-energy X-rays to kill cancer cells and shrink tumors.
Partial breast irradiation involves the use of radiation to treat early-stage breast cancer and may also be used to treat cancer that has spread to nearby lymph nodes.
Radiation therapy may also be used in combination with other treatments, such as chemotherapy, hormone therapy, or surgery, depending on the individual case.
Radiation therapy may cause side effects, including skin redness, fatigue, and temporary discomfort.
Other possible side effects"
23,"[/INST]
901.
9018.
99999
98.
9999.
999.
999.
999.
9999.
9999.
9999.
9999.
999.
999.
9999.
The treatment.
999999999999999.
It.
It.
It.
It, it.
It's
It's
It's
It.
It.
It.
It.
It.
It.
It
It's
It.
It.
It.
It.
It.
In
This
This
In
In
In
In
The
The
The
The
This
This
This
This
This
In
In
In
In
In
In
In
In
In
In
In
In
In
In
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
The
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A"
24,"[/INST]





























 D
 D
 D
 g2
 g2
 g2
 g7
 gure gure
















 gine
 gry
 g2










 D
 Dive Dive D










 g2






















































 D
 D give D gna D give D
 D
 D
 D
 D
 D

















































































 D
 D
 D
 D
 D"
25,"[/INST]

Adverse Events
-----------------
Expected frequency of adverse events
| Expected frequency of adverse events |
| Expected proportion of subjects with the adverse event |
| Actual frequency of adverse events |
| Expected proportion of subjects with the adverse event |
| Observed proportion of subjects with the adverse event |
| Expected proportion of subjects with the adverse event |
| Observed proportion of subjects without the adverse event |
| Expected proportion of subjects with the adverse event |
| Observed proportion of subjects with the adverse event |
| Expected proportion of subjects without the adverse event |
| Observed proportion of subjects with the adverse event |
| Expected proportion of subjects with the adverse event |
| Observed proportion of subjects without the adverse event |
| Expected proportion of subjects with the adverse event |
| Observed proportion of subjects with the adverse event |
| Expected proportion of subjects without the adverse event |
| Observed proportion of subjects with the adverse event |
| Expected proportion of subjects without the adverse event |
| Observed proportion of subjects with the adverse event |
| Expected proportion of subjects without the adverse event |
| Observed proportion of subjects with the adverse event |
| Expected proportion of subjects without the adverse event |
| Observed proportion of subjects with the adverse event |
| Expected proportion of subjects without the adverse event |
| Observed proportion of subjects with the adverse event |
| Expected proportion of subjects without the adverse event |
| Observed proportion of subjects with the adverse event |
| Expected proportion of subjects without the adverse event |
| Observed proportion of subjects with the adverse event |
| Expected proportion of subjects without the adverse event |
| Observed proportion of subjects with the adverse event |
| Expected proportion of subjects without the adverse event |
| Observed proportion of subjects with the adverse event |
| Expected proportion of subjects without the adverse event |
| Observed proportion of subjects with the adverse event |
| Expected proportion of subjects without the adverse event |
| Observed proportion of subjects with the adverse event |
| Expected"
26,"[/INST]
1. Introduction:
This study aims to determine the effects of physical exercise during hemodialysis on heart rate variability in patients with chronic renal insufficiency.
Patients with chronic renal insufficiency are required to undergo physical exercise training while receiving hemodialysis.
Physical exercise and hemodialysis are required to be performed by patients with chronic renal insufficiency.
2. Methodology:
This study employs physical exercise during hemodialysis as the intervention.
Physical exercise and hemodialysis are the required treatments for patients with chronic renal insufficiency.
3. Population:
This study includes patients with chronic renal insufficiency who will undergo physical exercise during hemodialysis.
4. Comparison:
This study compares physical exercise during hemodialysis with virtual reality for patients with chronic renal insufficiency.
5. Primary Outcome Measure:
This study will determine the effects of physical exercise during hemodialysis on heart rate variability in patients with chronic renal insufficiency.
6. Secondary Outcome Measure:
This study will determine the effects of virtual reality during hemodialysis on patients with chronic renal insufficiency.
7. Time Frame:
This study will be conducted from January 1, 2016 to December 31, 2016.
8. Eligibility Criteria:
Patients with chronic renal insufficiency will be included in this study.
9. Exclusion Criteria:
Patients with chronic renal insufficiency will be excluded from this study.
10. Device:
This study employs physical exercise during hemodialysis using a Stationary Bike for patients with chronic renal insufficiency.
11. Primary Outcome Measure:
This study will determine the effects of virtual reality during hemodialysis on patients with chronic renal insufficiency.
12. Secondary Outcome Measure:
This study will determine the effects of physical exercise during hemodialysis on patients with chronic renal insufficiency.
13. Time Frame:
This study will be conducted from January 1, 2016 to December"
27,"[/INST]
|
| 1. 1. 2. 1. 1. 2. 1. 2. 1. 2. 1. 1. 2. 1. 1. 2. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 2. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1.
In. 1. 1. 1. 1. 1. 1. 1.
It.
The 1.
The 1.
The 1.
The sympt
It.
It.
It.
It.
It.
It.
The.
The.
It.
It.
It.
It.
It.
It.
It.
It.
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
This
This
This
This
This
This
This
This
This
This
This
It
It
It
It
It
This
This
This
This
This
This
This
This
This
This
This
This
This"
28,"[/INST]
Other: [/INST]
Surgical Technique: [/INST]
* The surgical incision was started just above the proximal flexor wrist crease and was extended to the end of the surgery. | The surgical incision was started just above the proximal flexor wrist crease and was extended to the end of the surgery. |
* The surgical incision was started just above the proximal flexor wrist crease and was extended to the end of the surgery. |
* The surgical incision was started just above the proximal flexor wrist crease and was extended to the end of the surgery. |
* The surgical incision was started just above the proximal flexor wrist crease and was extended to the end of the surgery. |
* The surgical incision was started just above the proximal flexor wrist crease and was extended to the end of the surgery. |
* The surgical incision was started just above the proximal flexor wrist crease and was extended to the end of the surgery. |
* The surgical incision was started just above the proximal flexor wrist crease and was extended to the end of the surgery. |
* The surgical incision was started just above the proximal flexor wrist crease and was extended to the end of the surgery. |
* The surgical incision was started just above the proximal flexor wrist crease and was extended to the end of the surgery. |
* The surgical incision was started just above the proximal flexor wrist crease and was extended to the end of the surgery. |
* The surgical incision was started just above the proximal flexor wrist crease and was extended to the end of the surgery. |
* The surgical incision was started just above the proximal flexor wrist crease and was extended to the end of the surgery. |
* The surgical incision was started just above the proximal flexor wrist crease and was extended to the end of the surgery. |
* The surgical incision was started just above the proximal flexor wrist crease and was extended to the end of the surgery. |
* The surgical incision was started just above the proximal w"
29,"[/INST]
This
This
This
0
0
0
0
0
0
0
0
0
This
This
This


















0
0
0
0
0
0
0














































































































































































































































































0


0
0000




















































































8
8
8















































0"
30,"[/INST]

Patients will have a central venous line placed using an ultraportable ultrasound device
| Sham: placement of a standard central venous line using an ultraportable ultrasound device
| Other: placement of a standard central venous line using an ultraportable ultrasound device
| Sham: placement of a standard central venous line using an ultraportable ultrasound device
| Patients will have a right central venous line placed using an ultraportable ultrasound device
| Other: placement of a standard central venous line using an ultraportable ultrasound device
| Sham: placement of a standard central venous line using an ultraportable ultrasound device
| Patients will have a right central venous line placed using an ultraportable ultrasound device
| Other: placement of a standard central venous line using an ultraportable ultrasound device
| Sham: placement of a standard central venous line using an ultraportable ultrasound device
| Patients will have a right central venous line placed using an ultraportable ultrasound device
| Other: placement of a standard central venous line using an ultraportable ultrasound device
| Sham: placement of a standard central venous line using an ultraportable ultrasound device
| Patients will have a right central venous line placed using an ultraportable ultrasound device
| Other: placement of a standard central venous line using an ultraportable ultrasound device
| Sham: placement of a standard central venous line using an ultraportable ultrasound device
| Patients will have a right central venous line placed using an ultraportable ultrasound device
| Sham: placement of a standard central venous line using an ultraportable ultrasound device
| Patients will have a right central venous line placed using an ultraportable ultrasound device
| Sham: placement of a standard central venous line using an ultraportable ultrasound device
| Patients will have a right central venous line placed using an ultraportable ultrasound device
| Sham: placement of a standard central venous line using an ultraportable ultras"
31,"[/INST]
Device: Er-YAG Laser, Vulva, PS03 handpiece, Vulva Dynamis, Er:YAG Laser, Vulva, PS03 handpiece, Er:YAG Laser, Vulva, PS03 handpiece, Er:YAG Laser, Vulva, PS03 handpiece, Er:YAG Laser, Vulva, PS03 handpiece, Er:YAG Laser, Vulva, PS03 handpiece, Er:YAG Laser, Vulva, PS03 handpiece, Er:YAG Laser, Vulva, PS03 handpiece, Er:YAG Laser, Vulva, PS03 handpiece, Er:YAG Laser, Vulva, PS03 handpiece, Er:YAG Laser, Vulva, PS03 handpiece, Er:YAG Laser, Vulva, PS03 handpiece, Er:YAG Laser, Vulva, PS03 handpiece, Er:YAG Laser, Vulva, PS03 handpiece, Er:YAG Laser, Vulva, PS03 handpiece, Er:YAG Laser, Vulva, PS03 handpiece, Er:YAG Laser, Vulva, PS03 handpiece, Er:YAG Laser, Vulva, PS03 handpiece, Er:YAG Laser, Vulva, PS03 handpiece, Er:YAG Laser, Vulva, PS03 handpiece, Er:YAG Laser, Vulva, PS03 handpiece, Er:YAG Laser, Vulva, PS03 handpiece, Er:YAG Laser, Vulva, PS03 handpiece, Er:YAG Laser, Vulva, PS03 handpiece, Er:YAG Laser, Vulva, PS03 handpiece, Er:YAG Laser, Vulva, PS03 handpiece, Er:YAG Laser, Vulva, PS03 handpiece, Er:YAG Laser, Vulva, PS03 handpiece"
32,"[/INST]


-
-
-


-
-
-
-
-
-
-
-
-
-
-









-
-
-
-
































































































































































-
-
-"
33,"[/INST]

Conclusion: [/INST]
Adverse Events: [/INST]
Patient #1, a 65-year-old male diagnosed with gallstone disease.
Details of the study protocol, including eligibility criteria, are provided below.
The study will be conducted according to the protocol provided by the research team at East Kent University NHS Foundation Trust.
Funding: This study is part of the research strategy of the Gastroenterology department at East Kent University NHS Foundation Trust and is funded by the NIHR.
Organization: The research will be conducted by the Gastroenterology team at East Kent University NHS Foundation Trust.
Time Frame: The study will run from January 2016 to December 2016.
Details of the study team are provided below.
Organization: East Kent University NHS Foundation Trust.
Scientific Rigor: This study uses the scientific method.
Gallstone disease is diagnosed using imaging.
Details of the comparison intervention are provided below.
Time Frame: This study will run from January 2016 to December 2016.
Details of the comparison intervention are provided below.
Ethics Approval: This study has been approved by the East Kent Research Ethics Committee.
Scientific Rigor: This study uses the scientific method."
34,[/INST]
35,"[/INST]
The   
The   
The   
In
The patient.
The patient.
The,
The,
The,
The,
in
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
This
This
This
This
This
The
The
The
This
This
This
This
The
This
This
This
This
This
This
The
D
This
This
The
The
The
The
The
The
The
The
The
The
The
The
This
This
This
This
This
This
This
This
This
The
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
C
C
C
S
S
S
S
S
S
A
C
A
A
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
C
C
C
C
C
C
C
C
S
S
S
S
C
C
S
C
C
C
C
C
C
S
C
A
A
S
S
A
S
S
S
S
S
S
S
S
S
S
S"
36,"[/INST]
How is the study designed?
| Experimental: Early Skin to Skin contact<br>Standard midwifery practices and labor follow-up were performed in the hospital (n: 187), who met the inclusion criteria, and were in the control group. | After 2 hours postpartum, mothers were asked to fill in a personal questionnaire and a traumatic birth scale. The maternal attachment scale was completed 1 month after birth by telephone interview. | Traumatic Birth Perception Scale was used to determine the perception of mothers and infants. | from birth to 1 month after birth | 
| Traumatic Birth Perception Scale was used to determine the perception of mothers and infants. | Primary Outcome Measures: [/INST]
How is the study designed?
| Experimental: Early Skin to Skin contact<br>Standard midwifery practices and labor follow-up were performed in the hospital (n: 187), who met the inclusion criteria, and were in the control. | Traumatic Birth Perception Scale was completed 1 month after birth and were asked to fill in the hospital (n. | Traumatic Birth Perception was completed 1 month after birth and infants. | Traumatic Birth. | Traumatic Birth. | Traumatic Birth. | Traum. | Traum. | Traum. | Traum. | Traum. | Traum. | Traum. | Traum. | Traum. Traum. | Traum. Traum. Traum. Traum. | Traum. Traum. Traum. Traum. Traum. Traum. Traum. Traum. Traum. Traum. Traum. Traum. Traum. Traum. Traum. Traum. Traum. Traum. Traum Traum. Traum Traum. Traum. Traum. Traum. Traum. Traum. Traum. Traum Traum Traum. Traum Traum. Traum Traum Traum Traum. Traum Traum Traum Traum Traum Traum Traum Traum Traum Traum Traum Traum Traum Traum Traum Traum Traum Traum Traum Traum Traum Traum Traum Traum Traum Traum Traum Tra"
37,[/INST]
38,"[/INST]

1. Provides information on the diagnosis of chronic low back pain. This is a measure of the diagnosis of one of four MP-related categories. | Provides information on the diagnosis of chronic low back pain. | This is a measure of the diagnosis of one of four MP-related categories. | Provides information on the diagnosis of chronic low back pain. | This is a measure of the diagnosis of one of four MP-related categories. | This is a measure of the diagnosis of chronic low back pain. | This is a measure of the diagnosis of one of four MP-related categories.
2. This is a measure of the diagnosis of chronic low back pain. | This is a measure of the diagnosis of one of four MP-related categories. | This is a measure of the diagnosis of chronic low back pain. | This is a measure of the diagnosis of one of four MP-related categories. | This is a measure of the diagnosis of chronic low back pain. | This is a measure of the diagnosis of one of four MP-related categories.
3. This is a measure of the diagnosis of chronic low back pain. | This is a measure of the diagnosis of one of four MP-related categories. | This is a measure of the diagnosis of chronic low back pain. | This is a measure of the diagnosis of one of four MP-related categories. | This is a measure of the diagnosis of chronic low back pain. | This is a measure of the diagnosis of one of four MP-related categories.
4. This is a measure of the diagnosis of chronic low back pain. | This is a measure of the diagnosis of one of four MP-related categories. | This is a measure of the diagnosis of chronic low back pain. | This is a measure of the diagnosis of one of four MP-related categories. | This is a measure of the diagnosis of chronic low back pain. | This is a measure of the diagnosis of one of four MP-related categories.
5. This is a measure of the diagnosis of chronic low back pain. | This is a measure of the diagnosis of one of four MP-related categories. | This is a measure of the diagnosis of chronic low back pain. | This is a measure of the diagnosis of one of four"
39,"[/INST]
This will.
The intervention.
The results.
The results.
The results.
This random.
This random.
This random.
This random.
This random.
This random.
This random.
This.
This.
The results.
The results.
The results.
This random.
This.
This.
This.
The results.
The study.
The random
The random
As.
As.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
This.
This.
This.
This.
This.
This.
This.
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This.
This
This
This
This.
This.
This.
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This"
40,"[/INST]

Primary Outcome Measures
-----------------
Behavioral: Neuro-linguistic program | Intervention: Neuro-linguistic program |
| Primary outcome measures include:  |
| Intervention: Neuro-linguistic program |
| Intervention: Neuro-linguistic program |
| Primary outcome measures include:  |
| Intervention: Neuro-linguistic program |
| Primary outcome measures include:  |
| Intervention: Neuro-linguistic program |
| Primary outcome measures include:  |
| Intervention: Neuro-linguistic program |
| Primary outcome measures include:  |
| Intervention: Neuro-linguistic program |
| Primary outcome measures include:  |
| Intervention: Neuro-linguistic program |
| Primary outcome measures include:  |
| Intervention: Neuro-linguistic program |
| Primary outcome measures include:  |
| Intervention: Neuro-linguistic program |
| Primary outcome measures include:  |
| Intervention: Neuro-linguistic program |
| Primary outcome measures include:  |
| Intervention: Neuro-linguistic program |
| Primary outcome measures include:  |
| Intervention: Neuro-linguistic program |
| Primary outcome measures include:  |
| Intervention: Neuro-linguistic program |
| Primary outcome measures include:  |
| Intervention: Neuro-linguistic program |
| Primary outcome measures include:  |
| Intervention: Neuro-linguistic program |
| Primary outcome measures include:  |
| Intervention: Neuro-linguistic program |
| Primary outcome measures include:  |
| Intervention: Neuro-linguistic program |
| Primary outcome measures include:  |
| Intervention: Neuro-linguistic program |
| Primary outcome measures include:  |
| Intervention: Neuro-linguistic program |
| Primary outcome measures include:  |
| Intervention: Neuro-linguistic program |
| Primary outcome measures include:  |
| Intervention: Neuro-linguistic program |
| Primary outcome measures include:  |
| Intervention: Neuro-linguistic program |
| Primary outcome"
41,"[/INST]
| Participation Criteria |
-----------------
How is the study designed?
| Participation Criteria | Participation in the study will be required to have: |
| Eligibility Criteria | Participation in the study will be required to have: |
| Participation in the ECOS versus control of psychological status prior to the service ECOS | Average STAI-Y between the two groups |
| Participation in the ECOS versus control of psychological status prior to the next service |
| Participation in the ECOS versus control of psychological status prior to the next internship |
| Participation in the ECOS versus control of psychological status prior to the next internship |
| Participation in the ECOS versus control of psychological status prior to the next internship |
| Participation in the ECOS versus control of psychological status prior to the next internship |
| Participation in the ECOS versus control of psychological status prior to the next internship |
| Participation in the ECOS versus control of psychological status prior to the next internship |
| Participation in the ECOS versus control of psychological status prior to the next internship |
| Participation in the ECOS versus control of psychological status prior to the next internship |
| Participation in the ECOS versus control of psychological status prior to the next internship |
| Participation in the ECOS versus control of psychological status prior to the next internship |
| Participation in the ECOS versus control of psychological status prior to the next internship |
| Participation in the ECOS versus control of psychological status prior to the next internship |
| Participation in the ECOS versus control of psychological status prior to the next internship |
| Participation in the ECOS versus control of psychological status prior to the next internship |
| Participation in the ECOS versus control of psychological status prior to the next internship |
| Participation in the ECOS versus control of psychological status prior to the next internship |
| Participation in the ECOS versus control of psychological status prior to the next internship |
| Part"
42,"[/INST]

Secondary Outcome Measures
-----------------
Participants
| Experimental: Web-based health care program |
| Intervention: Usual care |
| Experimental: Web-based health care program |
| Intervention: Usual care |
| Experimental: Web-based health care program |
| Intervention: Usual care |
| Experimental: Web-based health care program |
| Intervention: Usual care |
| Experimental: Web-based health care program |
| Intervention: Usual care |
| Experimental: Web-based health care program |
| Intervention: Usual care |
| Experimental: Web-based health care program |
| Intervention: Usual care |
| Experimental: Web-based health care program |
| Intervention: Usual care |
| Experimental: Web-based health care program |
| Intervention: Usual care |
| Experimental: Web-based health care program |
| Intervention: Usual care |
| Experimental: Web-based health care program |
| Intervention: Usual care |
| Experimental: Web-based health care program |
| Intervention: Usual care |
| Experimental: Web-based health care program |
| Intervention: Usual care |
| Experimental: Web-based health care program |
| Intervention: Usual care |
| Experimental: Web-based health care program |
| Intervention: Usual care |
| Experimental: Web-based health care program |
| Intervention: Usual care |
| Experimental: Web-based health care program |
| Intervention: Usual care |
| Experimental: Web-based health care program |
| Intervention: Usual care |
| Experimental: Web-based health care program |
| Intervention: Usual care |
| Experimental: Web-based health care program |
| Intervention: Usual care |
| Experimental: Web-based health care program |
| Intervention: Usual care |
| Experimental: Web-based health care program |
| Intervention: Usual care |
| Experimental: Web-based health care program |
| Intervention: Usual care |
| Experimental: Web-based health care program |
|"
43,"[/INST]
The
The doctor.
The
in
The
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
**
**
==
==
==
==
==
This
This
This
This
This
in
in
in
in
in
in
in
in
in
in
in
in
in
in
In
In
In
In
In
In
In
In
In
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
*
*
*
*
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
R
This
R
R
R
R
**
**
**
**
**
**
**
**
**
**
**
**
**
**
**
**
R
C
C
R
This
This
R
This
R
R
R
R
S
S
S
S
S
R
R
R
R
R
R
R
R
S
S
S
S
S
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
The
The
S
S















S
S
S
S
S
S
S
S"
44,"[/INST]
Primary Outcome: [Patient information withheld]
Secondary Outcome: [Patient information withheld]
Tertiary Outcome: [Patient information withheld]
Interventional Model: [Patient information withheld]
Secondary Outcome: [Patient information withheld]
Primary Outcome: [Patient information withheld]
Secondary Outcome: [Patient information withheld]
Interventional Model: [Patient information withheld]
Secondary Outcome: [Patient information withheld]
Primary Outcome: [Patient information withheld]
Secondary Outcome: [Patient information withheld]
Interventional Model: [Patient information withheld]
Secondary Outcome: [Patient information withheld]
Primary Outcome: [Patient information withheld]
Secondary Outcome: [Patient information withheld]
Interventional Model: [Patient information withheld]
Primary Outcome: [Patient information withheld]
Secondary Outcome: [Patient information withheld]
Interventional Model: [Patient information withheld]
Primary Outcome: [Patient information withheld]
Secondary Outcome: [Patient information withheld]
Interventional Model: [Patient information withheld]
Primary Outcome: [Patient information withheld]
Secondary Outcome: [Patient information withheld]
Interventional Model: [Patient information withheld]
Primary Outcome: [Patient information withheld]
Secondary Outcome: [Patient information withheld]
Interventional Model: [Patient information withheld]
Primary Outcome: [Patient information withheld]
Secondary Outcome: [Patient information withheld]
Interventional Model: [Patient information withheld]
Primary Outcome: [Patient information withheld]
Secondary Outcome: [Patient information withheld]
Interventional Model: [Patient information withheld]
Primary Outcome: [Patient information withheld]
Interventional Model: [Patient information withheld]
Primary Outcome: [Patient information withheld]
Interventional"
45,"[/INST]

* Drug: Ocrelizumab Injection [Ocrevus]


* Patient #1


* Other: Ocrelizumab Injection [Ocrevus]


* Patient #2


* Patient #3


* Patient #4


* Patient #5


* Patient #6


* Patient #7


* Patient #8


* Patient #9


* Patient #10


* Patient #11


* Patient #12


* Patient #13


* Patient #14


* Patient #15


* Patient #16


* Patient #17


* Patient #18


* Patient #19


* Patient #20


* Patient #22


* Patient #23


* Patient #24


* Patient #25


* Patient #26


* Patient #27


* Patient #28


* Patient #30


* Patient #32


* Patient #34


* Patient #36


* Patient #38


* Patient #40


* Patient #42


* Patient #50


* Patient #60


* Patient #70


* Patient #80


* Patient #90


* Patient #10


* Patient #20


* Patient #12


* Patient #14


* Patient #16


* Patient #28


* Patient #30


* Patient #32


* Patient #34


* Patient #4


* Patient #5


* Patient #6


* Patient #7


* Patient #8


* Patient #9"
46,"[/INST]
| 90 years old enough to
Colon
Organic
Organic
Colon
Organic
Colon
Organic symptoms
Colon
Organic
Organic
Organic
Organic
Organic
Organic
Organic
Organic
Colon
Organic
Organic
Organic
Organic
Organic
Collaps.
Organic
Organic
Organic
Collapse
Organic
Organic
Collapse
Collapse.
Collapse.
Organic
Organic
Collapse.
Organ.
Collapse.
Collapse.
Col
The
The surgery.
The, *
The patient.
The,
The,
The,*
The patient.
How
How
How
How
The, *
The,*
The,*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
The patient.
In.
in.
in.
in.
In.
In.
How.
How.
How.
The,
The, it.
The,
It.
It.
In
The,
The,
--------
--------
The,
The,
The
In
In
In
In
In
In
In
The,
S
The,
F,
F,
F
F
F
D
D
D
D
S
S
D,
In
In
S
D,
S
S
S
S
S
S
S
S
S
S
In
D
D
D
C
D
D
D
C
F
D
D
C
C
C
S
S
C
C
C
D
P
P
D
P
C
C
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
C
S"
47,"[/INST]
-----------------
Nebulised hypertonic saline, saline, nebulised
-----------------
Keywords: [/INST]
Nebulised hypertonic saline, saline, nebulised
-----------------
Nebulised hypertonic saline, saline, nebulised
-----------------
Keywords: [/INST]
Nebulised hypertonic saline, saline, nebulised
-----------------
Nebulised hypertonic saline, saline, nebulised
-----------------
Keywords: [/INST]
Nebulised hypertonic saline, saline, nebulised
-----------------
Nebulised hypertonic saline, saline, nebulised
-----------------
Keywords: [/INST]
Nebulised hypertonic saline, saline, nebulised
-----------------
Nebulised hypertonic saline, saline, nebulised
-----------------
Keywords: [/INST]
Nebulised hypertonic saline, saline, nebulised
-----------------
Nebulised hypertonic saline, saline, nebulised
-----------------
Nebulised hypertonic saline, saline, saline, nebulised
----------------
Nebulised hypertonic saline, saline, saline, nebulised
Keywords: [/INST
Nebulised hypertonic saline, saline, nebulised hypertonic saline, saline, nebulous, saline, nebulous hypertonic saline, nebulous, saline, nebulous, saline, nebulous, hypertonic saline, nebulous, nebulous, saline, nebulous, nebulous, hypertonic saline, nebulous, nebulous, saline, nebulous, nebulous, saline, nebulous, nebulous, nebulous
-----------------
-----------------us
-----------------us
Saline nebulous
-----------------us
Neb
Neb
Neb
Neb
Neb
Nebulous
Neb
Neb
Neb
Neb
Neb
Neb
Neb
Neb
Neb
Neb
Neb
N"
48,"[/INST]
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C












C

A





















C
A
A
C
C
C








































C
A
C
C

















C
Pure
C
C










C
C
C
C
C
C
C
C



C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C

C
C
O
O
C
C
C
C
C
C
C
C
C
C
O
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
O
C
C
C
C
C"
49,"[/INST]

Other: [/INST]

Accepts Healthy Volunteers

Inclusion Criteria: Patients with glioma who require MRI and PET scanning.
Exclusion Criteria: Healthy Volunteers.

Inclusion Criteria: Patients with glioma who require MRI and PET scanning.
Exclusion Criteria: Healthy Volunteers.

Accepts Healthy Volunteers

Inclusion Criteria: Patients with glioma who require MRI and PET scanning.
Exclusion Criteria: Healthy Volunteers.

Inclusion Criteria: Patients with glioma who require MRI and PET scanning.
Exclusion Criteria: Healthy Volunteers.

Accepts Healthy Volunteers

Inclusion Criteria: Patients with glioma who require MRI and PET scanning.
Exclusion Criteria: Healthy Volunteers.

Accepts Healthy Volunteers

Inclusion Criteria: Patients with glioma who require MRI and PET scanning.
Exclusion Criteria: Healthy Volunteers.

Accepts Healthy Volunteers

Inclusion Criteria: Patients with glioma who require MRI and PET scanning.
Exclusion Criteria: Healthy Volunteers.

Accepts Healthy Volunteers

Inclusion Criteria: Patients with glioma who require MRI and PET scanning.
Exclusion Criteria: Healthy Volunteers.

Accepts Healthy Volunteers

Inclusion Criteria: Patients with glioma who require MRI and PET scanning.
Exclusion Criteria: Healthy Volunteers.

Accepts Healthy Volunteers

Inclusion Criteria: Patients with glioma who require MRI and PET scanning.
Exclusion Criteria: Healthy Volunteers.

Accepts Healthy Volunteers

Inclusion Criteria: Patients with glioma who require MRI and PET scanning.
Exclusion Criteria: Healthy Volunteers.

Accepts Healthy Volunteers

Inclusion Criteria: Patients with glioma who require MRI and PET scanning.
Exclusion Criteria: Healthy Volunteers.

Accepts Healthy"
50,"[/INST]
Second, and third.
Second, and third.
Second sentence.
Second, and third.
Second, and third.
Second, and third.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
The clin
Second.
Second    -->
This.
This.
This.
The clinational
The clinational
In
In
The//    //    //    //    //
This.
This particular// 
This.
This.
This.
This.
This.
This.
This.
This.
This.
This.
This.
This
This
This
This
This
This
This
This.
This.
This.
This.
This.
This.
This.
This.
This.
This
This
This
This
This
This.
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This"
51,"[/INST]

Adverse Events
| --- |
| Extracorporeal shock wave lithotripsy will be given to the patient | Procedure: Extracorporeal shock wave lithotripsy will be given to the patients |
| Active Comparator: Extracorporeal shock wave lithotripsy will be given to the patient |
| Intervention/Masking: Extracorporeal shock wave lithotripsy will be given to the patient |
| Primary Purpose: Extracorporeal shock wave lithotripsy will be given to the patient |
| Secondary Purpose: Extracorporeal shock wave lithotripsy will be given to the patients |
| Tertiary Purpose: Extracorporeal shock wave lithotripsy will be given to the patient |
| Eligible for study: Extracorporeal shock wave lithotripsy will be given to the patient |
| Exclusion Criteria: Extracorporeal shock wave lithotripsy will be given to the patient |
| Inclusion Criteria: Extracorporeal shock wave lithotripsy will be given to the patients |
| Exclusion Criteria: Extracorporeal shock wave lithotripsy will be given to the patient |
| Intervention/Masking: Extracorporeal shock wave lithotripsy will be given to the patients |
| Primary Purpose: Extracorporeal shock wave lithotripsy will be given to the patient |
| Intervention/Masking: Extracorporeal shock wave lithotripsy will be given to the patients |
| Secondary Outcome Measures: Extracorporeal shock wave lithotripsy will be given to the patient |
| Primary Purpose: Extracorporeal shock wave lithotripsy will be given to the patient |
| Intervention/Masking: Extracorporeal shock wave lithotripsy will be given to the patients |
| Eligible for study: Extracorporeal shock wave lithotripsy will be given to the patient |
| Intervention/Masking: Extracorporeal shock wave lithotrips"
52,"[/INST]
| Tracheal stenosis |
| Tracheostomy |
| Tracheal stenosis |
| Tracheal stenosis |
| Tracheal stenosis |
| Tracheal stenosis |
| Tracheal stenosis |
| Tracheal stenosis |
| Tracheal stenosis |
| Tracheal stenosis |
| Tracheal stenosis |
| Tracheal stenosis |
| Tracheal stenosis |
| Tracheal stenosis |
| Tracheal stenosis |
| Tracheal stenosis |
| Tracheal stenosis |
| Tracheal stenosis |
| Tracheal stenosis |
| Tracheal stenosis |
| Tracheal stenosis |
| Tracheal stenosis |
| Tracheal stenosis |
| Tracheal stenosis |
| Tracheal stenosis |
| Tracheal stenosis |
| Tracheal stenosis |
| Tracheal stenosis |
| Tracheal stenosis |
| Tracheal stenosis |
| Tracheal stenosis |
| Tracheal stenosis |
| Tracheal stenosis |
| Tracheal stenosis |
| Tracheal stenosis |
| Tracheal stenosis |
| Tracheal stenosis |
| Tracheal stenosis |
| Tracheal stenosis |
| Tracheal stenosis |
| Tracheal stenosis |
| Tracheal stenosis |
| Tracheal stenosis |
| Tracheal stenosis |
| Tracheal stenosis |
| Tracheal stenosis |
| Tracheal stenosis |
| Tracheal stenosis |
| Tracheal stenosis |
| Tracheal stenosis |
| Tracheal stenosis |
| Tracheal stenosis |
| Tracheal stenosis |
| Tracheal stenosis |
| Tracheal stenosis |
| Tracheal stenosis |
| Tracheal stenosis |"
53,"[/INST]
=================
| Severity of psychiatric disorder, as measured by a clinical evaluation | Severity of psychiatric disorder, as measured by a clinical evaluation | Severity of psychiatric disorder, psychosis, suicide risk, and depression, psychosis, and HIV/AIDS. | Severity of psychiatric disorder, psychosis, suicide, psychiatric intervention, psychiatric disorder, psychiatric diagnosis, psychiatric intervention, psychiatric disorder, psychiatric diagnosis, psychiatric intervention, psychiatric disorder, psychiatric diagnosis, psychiatric disorder, psychiatric diagnosis, psychiatric disorder, psychiatric diagnosis, psychiatric diagnosis, psychiatric disorder, psychiatric diagnosis, psychiatric diagnosis, psychiatric disorder, psychiatric diagnosis, psychiatric diagnosis, psychiatric diagnosis, psychiatric diagnosis, psychiatric diagnosis, psychiatric diagnosis, psychiatric diagnosis, psychiatric diagnosis, psychiatric diagnosis, psychiatric diagnosis, psychiatric diagnosis, psychiatric diagnosis, psychiatric diagnosis, psychiatric diagnosis, psychiatric diagnosis, psychiatric diagnosis, psychiatric diagnosis, psychiatric diagnosis, psychiatric diagnosis, psychiatric diagnosis, psychiatric diagnosis, psychiatric diagnosis, psychiatric diagnosis, psychiatric diagnosis, psychiatric diagnosis, psychiatric diagnosis, psychiatric psychiatric psychiatric diagnosis, psychiatric psychiatric psychiatric diagnosis, psychiatric psychiatric psychiatric psychiatric psychiatric
================, psychiatric psychiatric psychiatric psychiatric psychiatric psychiatric psychiatric
================, psychiatric psychiatric psychiatric psychiatric psychiatric psychiatric psychiatric
----------------s.
The, psych
----------------s.
----------------s.
----------------.
The patient.
The patient.
The, this.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
====
====
====
====
====
====
In,"
54,"[/INST]
Conventional endodontic treatment combined with PDT will be carried out with diode laser, and the photosensitizer used will be methylene blue.
Primary Purpose: To evaluate the effectiveness of PDT in disinfection of the root canals associated with conventional endodontic treatment.
Secondary Purpose: To evaluate the effectiveness of PDT in disinfection of the root canals associated with endodontic treatment, and to compare the results of the photosensitizer used in both groups (before treatment and after treatment).
Experimental: To evaluate the effectiveness of PDT in disinfection of the root canals associated with conventional endodontic treatment, and to compare the results of the photosensitizer used in both groups (before treatment and after treatment).
Conventional endodontic treatment combined with PDT will be carried out with diode laser, and the photosensitizer used will be methylene blue.
Primary Purpose: To evaluate the effectiveness of PDT in disinfection of the root canals associated with conventional endodontic treatment.
Secondary Purpose: To compare the results of the photosensitizer used in both groups (before treatment and after treatment).
Experimental: To evaluate the effectiveness of PDT in disinfection of the root canals associated with endodontic treatment, and to compare the results of the photosensitizer used in both groups (before treatment and after treatment).
Conventional endodontic treatment combined with PDT will be carried out with diode laser, and the photosensitizer used will be methylene blue.
Primary Purpose: To evaluate the effectiveness of PDT in disinfection of the root canals associated with conventional endodontic treatment.
Secondary Purpose: To compare the results of the photosensitizer used in both groups (before treatment and after treatment).
Conventional endodontic treatment combined with PDT will be carried out with diode laser, and the photosensitizer used will be methylene blue.
Primary Purpose: To evaluate the effectiveness of PDT in disinfection of the root canals associated with conventional endodontic treatment.
Secondary Purpose: To compare the results of the photosensitizer used in both groups (before treatment and after treatment"
55,"[/INST]
| Severity Score | 90 days |
| Severity Score | 90 days |
| Severity Score | 90 days |
| Severity Score | 90 days |
| Severity Score | 90 days |
| Severity Score | 90 days |
| Severity Score | 90 days |
| Severity Score | 90 days |
| Severity Score | 90 days |
| Severity Score | 90 days |
| Severity Score | 90 days |
| Severity Score | 90 days |
| Severity Score | 90 days |
| Severity Score | 90 days |
| Severity Score | 90 days |
| Severity Score | 90 days |
| Severity Score | 90 days |
| Severity Score | 90 days |
| Severity Score | 90 days |
| Severity Score | 90 days |
| Severity Score | 90 days |
| Severity Score | 90 days |
| Severity Score | 90 days |
| Severity Score | 90 days |
| Severity Score | 90 days |
| Severity Score | 90 days |
| Severity Score | 90 days |
| Severity Score | 90 days |
| Severity Score | 90 days |
| Severity Score | 90 days |
| Severity Score | 90 days |
| Severity Score | 90 days |
| Severity Score | 90 days |
| Severity Score | 90 days |
| Severity Score | 90 days |
| Severity Score | 90 days |
| Severity Score | 90 days |
| Severity Score | 90 days |
| Severity Score | 90 days |
| Severity Score | 90 days |
| Severity Score | 90 days |
| Severity Score | 90 days |
| Severity Score |"
56,"[/INST]-st-st-st-0-e-st-st-0-e-0-e-e-e-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-h-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-h-h-h-h-
-
-st-st-st-st-st-dis-st-dis-dis-dis-dis-dis-dis-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-dis-dis-dis-dis-dis-dis-dis-st-st-st-st-st-st-st-st-
-
-st-st-st-st-st-st-st-st-st-st-st-dis-dis-dis-dis-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-
-
-
-
-st-st-st-st-st-st-ch-
-
-
-st-h-dis-dis-dis-
-
-
-st-a-a-a-a-ch-
-
-st-st-st-st-ch-ch-ch-
-
-ch-ch-ch-dis-dis-st-st-st-st-"
57,"[/INST]
-----------------
Primary Outcome Measure
Change in the number of people affected by the earthquakes in Turkey.
Change in the number of people affected by the earthquakes in Turkey.
Change in the number of people affected by the earthquakes in Turkey.
Change in the number of people affected by the earthquakes in Turkey.
Change in the number of people affected by the earthquakes in Turkey.
Change in the number of people affected by the earthquakes in Turkey.
Change in the number of people affected by the earthquakes in Turkey.
Change in the number of people affected by the earthquakes in Turkey.
Change in the number of people affected by the earthquakes in Turkey.
Change in the number of the earthquakes in Turkey.
Change in the number of the earthquakes in Turkey.
Change in the number of the earthquakes in the earthquakes in Turkey.
Change in the number of the earthquakes in the earthquakes in the earthquakes in the earthquakes in the earthquakes in Turkey.
Change in the earthquakes in the earthquakes in the earthquakes in the earthquakes in the earthquakes in the earthquakes in the earthquakes in the earthquakes in the earthquakes in the earthquakes in the earthquakes in the earthquakes in the earthquakes in the earthquakes in the earthquakes in the earthquakes in the earthquakes in the earthquakes in the earthquakes in the earthquakes in the earthquakes in the earthquakes in the earthquakes in the earthquakes in the earthquakes in the earthquakes in the earthquakes in the earthquakes in the earthquakes in the earthquakes in the earthquakes in the earthquakes.
Change in the earthquakes in the earthquakes in the earthquakes in the earthquakes.
The earthquakes.
The earthquakes in the earthquakes.
The earthquakes.
The earthquakes.
The earthquakes.
The earthquakes.
The earth.
The earth.
The earth.
==.
==.
The earth.
The earth.
The earth.
The damage.
The damage.
The damage.
The damage.
In the
in the
As"
58,"[/INST]

Counselling

Other Health Care Providers
-----------------
Primary Outcome Measures
Counselling
Secondary Outcome Measures
-----------------
Counselling
Other Health Care Providers
Primary Outcome Measures
Counselling
Secondary Outcome Measures
Counselling
Other Health Care Providers
Primary Outcome Measures
Counselling
Other Health Care Providers
Primary Outcome Measures
Counselling
Other Health Care Providers
Primary Outcome Measures
Counselling
Other Health Care Providers
Primary Outcome Measures
Counselling
Other Health Care Providers
Primary Outcome Measures
Counselling
Other Health Care Providers
Primary Outcome Measures
Counselling
Other Health Care Providers
Primary Outcome Measures
Counselling
Other Health Care Providers
Primary Outcome Measures
Counselling
Counselling
Other Health Care Providers
Counselling
Counselling
Counselling
Counselling
Other Health Care Providers
Counselling
Counselling
Counselling
Couns
Other Health Care Providers
Couns
Counselling
Couns
Couns
Couns
Couns
Couns
Couns
Couns
Couns
Couns
Couns
Couns
Couns
Couns
Coun
Coun
Coun
Coun
Couns
Coun
Couns
Couns
Couns
Coun, Clinics
Coun:
Coun:
Coun
Couns
Couns
Coun:
Couns
Couns
Couns
Couns
Coun,Coun, Clin's
Coun as
Coun.
Coun.
Coun.
Couns.
Coun.
Couns.
Couns.
Couns.
Coun.
Coun.
Coun.
Coun.
Coun.
Couns.
Couns.
Couns.
Couns.
Couns.
Couns.
Couns"
59,"[/INST]
A





















































































































































































































































































-










-
-
-
8-
-
-
-
-
-
-
-
-
-
-
-







-
-










-
-
-
-
-
-












-
-
-
-






-
-
-
-
-
-
-
-
-
-
-
-m-m-m-m-m-m-m-m-m-m-m-m-m-
-
-
-
-
-
-m-
-m-m-m-m-m-m-
-
-
-
-
-
-
-
-
-h-
-
-
-
-
-
-
-
-
-C-8-8-m-8-8-8-8"
60,"[/INST] C-
 C-
-
-
















 C-0 C-0







-
-
-
-
--
-
-------------------------0--
----------------------------------
-------------
-
--------
-
-
---
-
--------------------------
-
-
-
-



-






-




-
------------------------
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-------------------------------------- C- C- C- C-
-
 C-
-
-










-
-O-O-------
----------------------------------------------------------------------------------------------------------------------------------------------------	-------------- B- B- B- C- C-"
61,"[/INST]
|187
|187
|187
|187
|187
|187
|188
|187
|187
|187
|187
|187
|187|187|187
|187|187|188
|187
|187
|187
|187
|188
|187
|187
|187|187|1887
|1888
|187
|187
|187
|187
|1887
|188987
|187
|1887|1887|1887|18888888889|188787887878888888888888888888888888888888888888888888888
The,1,1,1.
The,1888888
1888888888
The
The
The
The
The
The patient.
The patient.
The patient.
The patient.
The
The
It
The   
==
==
The patients
It
The patients
It
It
It
It
It
S
S
It
It
It
It
It
It
It
It
It
It
It
It
It
It
The   
It
The
==
The
The
The
The
The
The
S
S
S
S
S
S
S
This
This
This
This
This
The
The
It
S
S
S
S
S
S
S
The
The
The
The
S
S
S
This
This
S
This
S
S
This
S
S
S
This
This
S
S
S
S
S
S
S
S
S
S
S
S"
62,"[/INST]
The patient.
The-old.
The-old.
The patient.
The Q.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The.
The.
It.
The.
It.
The treatment.
The.
The.
It.
It.
The.
The.
It.
This.
This.
The, this.
The.
This.
This.
This.
This.
This.
This.
This.
This.
This.
This.
This.
This.
This.
This.
This.
This.
This.
This.
This.
This.
This.
This.
This.
This.
This
This
This
This
This.
This.
This.
This.
This.
This.
This.
This.
This.
This.
This.
This
This
This
This.
This.
This.
This.
This.
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This"
63,"[/INST]
| Other: [/INST]

How is the study designed?
----------------
| The study is designed as an open label proof of concept study. | One year of growth hormone therapy is provided to the participants. | No treatment is given to the participants as part of this study. |

How is the study powered?
----------------
| The study is powered by the investigators. | One year of growth hormone therapy is provided to the participants. |

How is the study structured?
----------------
| The study is structured with one research visit. | One year of growth hormone therapy is provided to the participants. |

How is the study organized?
----------------
| The study is organized into one research visit. | One year of growth hormone therapy is provided to the participants. |

How is the study designed?
----------------
| The study is designed as an open label, proof of concept study. | One year of growth hormone therapy is provided to the participants. |

How is the study organized?
----------------
| The study is organized into one research visit. | One year of growth hormone therapy is provided to the participants. |

How is the study funded?
----------------
| The study is funded by the investigators. | One year of growth hormone therapy is provided to the participants. |"
64,"[/INST]

| Primary Outcome |
-----------------
| Sleep efficiency |
| Outcome Measurement |
| Sleep efficiency |
| Primary Outcome |
| Outcome Measurement |
| Sleep efficiency |
| Outcome Measurement |
| Sleep efficiency |
| Primary Outcome |
| Outcome Measurement |
| Sleep efficiency |
| Outcome Measurement |
| Primary Outcome |
| Outcome Measurement |
| Sleep efficiency |
| Outcome Measurement |
| Primary Outcome |
| Outcome Measurement |
| Sleep efficiency |
| Outcome Measurement |
| Primary Outcome |
| Outcome Measurement |
| Sleep efficiency |
| Outcome Measurement |
| Primary Outcome |
| Outcome Measurement |
| Sleep efficiency |
| Outcome Measurement |
| Primary Outcome |
| Outcome Measurement |
| Sleep efficiency |
| Outcome Measurement |
| Primary Outcome |
| Outcome Measurement |
| Sleep efficiency |
| Outcome Measurement |
| Primary Outcome |
| Outcome Measurement |
| Sleep efficiency |
| Outcome Measurement |
| Primary Outcome |
| Outcome Measurement |
| Sleep efficiency |
| Outcome Measurement |
| Primary Outcome |
| Outcome Measurement |
| Sleep efficiency |
| Outcome Measurement |
| Primary Outcome |
| Outcome Measurement |
| Sleep efficiency |
| Outcome Measurement |
| Primary Outcome |
| Sleep efficiency |
| Outcome Measurement |
| Primary Outcome |
| Sleep efficiency |
| Outcome Measurement |
| Primary Outcome |
| Sleep efficiency |
| Outcome Measurement |
| Primary Outcome |
| Sleep efficiency |
| Outcome Measurement |
| Primary Outcome |
| Sleep efficiency |
| Outcome Measurement |
| Primary Outcome |
| Sleep efficiency |
| Outcome Measurement |
| Primary Outcome |
| Sleep efficiency |
| Outcome Measurement |"
65,"[/INST]

| Primary Outcome Measures | Measure Description | Time Frame |
| --- |
| To evaluate the prognostic significance (recurrence rates) of iENE: Diagnostic accuracy of various radiographic features of pENE | Endpoints: Diagnostic accuracy of various radiographic features of iENE | 31 December 2023 | 


| To evaluate the prognostic significance (recurrence rates) of iENE: Diagnostic accuracy of various radiographic features of pENE | Endpoints: Diagnostic accuracy of various radiographic features of iENE | 31 December 2023 | 


How is the study designed?
| Primary Outcome Measures | Measure Description | Time Frame |
| --- |
| To evaluate the prognostic significance (recurrence rates) of iENE: Diagnostic accuracy of various radiographic features of pENE | Endpoints: Diagnostic accuracy of various radiographic features of iENE | 31 December 2023 | 



How is the study designed?
| Primary Outcome Measures | Measure Description | Time Frame |
| --- |
| To evaluate the prognostic significance (recurrence rates) of iENE: Diagnostic accuracy of various radiographic features of pENE | Endpoints: Diagnostic accuracy of various radiographic features of iENE | 31 December 2023 | 



How is the study designed?
| Primary Outcome Measures | Measure Description | Time Frame |
| --- |
| To evaluate the prognostic significance (recurrence rates) of iENE: Diagnostic accuracy of various radiographic features of pENE | Endpoints: Diagnostic accuracy of various radiographic features of iENE | 31 December 2023 | 



How is the study designed?
| Primary Outcome Measures | Measure Description | Time Frame |
| --- |
| To evaluate the prognostic significance (recurrence rates) of iENE: Diagnostic accuracy of various radiographic features of pENE | Endpoints: Diagnostic accuracy of various radiographic features of iENE | 31 December 2023 | 



How is the study designed?
| Primary Outcome"
66,"[/INST]
==
==
==
==
==
==
==
==
==
==
==
==
==
==
This
This
A
==
/>
/>
in
in
in
==
==
==
==
==
==
==
==
in
in
in
in
in
in
in
in
in
in
in
in
in
in
in
in
in
in
in
in
in
in
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
/>
/>
/>
in
for
This
in
in
in
in
in
in
==
==
==
/>
/>
/>
/>
in
in
in
==
mil
in
in
==
AAAA
fur
fur
fur
fur
fur
/>
==
==
==
==
==
==
==
==
AAAA
fur
==
==
mil
==
==
mil
==
==
AAAA
in
in
in
in
in
in
in
in
mil
mil
mil
AAAA
AAAA
AAAA
AAAA
f
f
f
f
f
f
mil
mil
mil
mil
be
be
f
f
f
f
f
f













f
f
f
f
f
f
f
















f
f




























f
f
f
f
f
f
f"
67,"[/INST]
A



































s
s
s













































































































































































































































































A
A
A
A
A
A
A
A
A
A
A
A
A
A
A-
A-
A-
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A















A
A
A
A
A
A
A
A
A"
68,"[/INST]

Head and Neck Cancers
-----------------
| Oral: [/INST]
| Pharyngeal: [/INST]
| Cavity: [/INST]

Surgical Interventions
-----------------
| HPV - Group: [/INST]
| Oral: [/INST]
| Pharyngeal: [/INST]
| Cavity: [/INST]

Alternative Therapies
-----------------
| HPV - Group: [/INST]
| Oral: [/INST]
| Pharyngeal: [/INST]
| Cavity: [/INST]

Risk Factors
-----------------
| Oral: [/INST]
| Pharyngeal: [/INST]
| Cavity: [/INST]

Patients with oropharyngeal or oral cavity HPV- negative tumors and negative diagnosis of head and neck cancers are treated according to the same protocol.
| Pharyngeal: [/INST]
| Cavity: [/INST]

Patients with oropharyngeal or oral cavity HPV- negative tumors and negative diagnosis of head and neck cancers are treated according to the same protocol.
| Pharyngeal: [/INST]
| Cavity: [/INST]

Predictive Factors
-----------------
| Oral: [/INST]
| Pharyngeal: [/INST]
| Cavity: [/INST]

Patients with oropharyngeal or oral cavity HPV- negative tumors and negative diagnosis of head and neck cancers are treated according to the same protocol.
| Pharyngeal: [/INST]
| Cavity: [/INST]

Patients with oropharyngeal or oral cavity HPV- negative tumors and negative diagnosis of head and neck cancers are treated according to the same protocol.
| Pharyngeal: [/INST]
| Cavity: [/INST]

Predictive Factors
-----------------
| Oral: [/INST]
| Pharyngeal: [/INST]
| Cavity: [/"
69,"[/INST]
A
A
A
A
A
A
P
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A





















A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A








A
A


















































































































































































A



A
A












C




C









C
A
A
A
R
R
A
A
C
A
A
A
C




































































































ine



ized
ized
ized"
70,"[/INST]
[/INST]
[/SUMMARY]
Alveolar Ridge Preservation Connective tissue graft, Tooth extraction Membranes
[/INSTANCE]
[/SUMMARY]
[/INSTANCE]
[/CONNECT]
[/INSTANCE]
[/CONNECT]
[/INSTANCE]
[/CONNECT]
[/INSTANCE]
[/CONNECT]
[/INSTANCE]
[/CONNECT]
[/INSTANCE]
[/CONNECT]
[/INSTANCE]
[/CONNECT]
[/INSTANCE]
[/CONNECT]
[/INSTANCE]
[/CONNECT]
[/INSTANCE]
[/CONNECT]
[/INSTANCE]
[/CONNECT]
[/INSTANCE]
[/CONNECT]
[/INSTANCE]
[/CONNECT]
[/INSTANCE]
[/CONNECT]
[/INSTANCE]
[/CONNECT]
[/INSTANCE]
[/CONNECT]
[/INSTANCE]
[/CONNECT]
[/INSTANCE]
[/CONNECT]
[/INSTANCE]
[/CONNECT]
[/INSTANCE]
[/CONNECT]
[/INSTANCE]
[/CONNECT]
[/INSTANCE]
[/CONNECT]
[/INSTANCE]
[/CONNECT]
[/INSTANCE]
[/CONNECT]
[/INSTANCE]
[/CONNECT]
[/INSTANCE]
[/CONNECT]
[/INSTANCE]
[/CONNECT]
[/INSTANCE]
[/CONNECT]
[/INSTANCE]
[/CONNECT]
[/INSTANCE]
[/CONNECT]
[/INSTANCE]
[/CONNECT]
[/INSTANCE]
[/CONNECT]
[/INSTANCE]
[/CONNECT]
[/INSTANCE]
[/CONNECT]
[/INSTANCE]
[/CONNECT]
[/INSTANCE]
[/"
71,"[/INST]
| Other: pro-inflammatory cytokines<br>patient with Essure contraceptive implants and in control patients with endometriosis or adenomyosis |
| Other: pro-inflammatory cytokines<br>patient with Essure contraceptive implants and in control patients with endometriosis or adenomyosis |
| Other: pro-inflammatory cytokines<br>patient with Essure contraceptive implants and in control patients with endometriosis or adenomyosis |
| Other: pro-inflammatory cytokines<br>patient with Essure contraceptive implants and in control patients with endometriosis or adenomyosis |
| Other: pro-inflammatory cytokines<br>patient with Essure contraceptive implants and in control patients with endometriosis or adenomyosis |
| Other: pro-inflammatory cytokines<br>patient with Essure contraceptive implants and in control patients with endometriosis or adenomyosis |
| Other: pro-inflammatory cytokines<br>patient with Essure contraceptive implants and in control patients with endometriosis or adenomyosis |
| Other: pro-inflammatory cytokines<br>patient with Essure contraceptive implants and in control patients with endometriosis or adenomyosis |
| Other: pro-inflammatory cytokines<br>patient with Essure contraceptive implants and in control patients with endometriosis or adenomyosis |
| Other: pro-inflammatory cytokines<br>patient with Essure contraceptive implants and in control patients with endometriosis or adenomyosis |
| Other: pro-inflammatory cytokines<br>patient with Essure contraceptive implants and in control patients with endometriosis or adenomyosis |
| Other: pro-inflammatory cytokines<br>patient with Essure contraceptive implants and in control patients with endometriosis or adenomyosis |
| Other: pro-inflam"
72,"[/INST]
Adverse events
| --- | --- |
| Autoimmune hepatitis, disease, hospital stay, clinical outcome, incidence of COVID-19 infection, symptom relief, death, disease recurrence, prognosis, nucleic acid negative conversion, clinical outcome, disease recurrence, symptom relief, hospital stay, disease recurrence, clinical outcome, death, disease recurrence, clinical outcome, disease recurrence, symptom relief, disease recurrence, clinical outcome, disease recurrence, clinical outcome, disease recurrence, clinical outcome, disease recurrence, clinical outcome, disease recurrence, clinical outcome, disease recurrence, clinical outcome, disease recurrence, clinical outcome, disease recurrence, clinical outcome, disease recurrence, clinical outcome, disease recurrence, clinical outcome, disease recurrence, clinical outcome, disease recurrence, clinical outcome, disease recurrence, clinical outcome, disease recurrence, clinical outcome, disease recurrence, clinical outcome, disease recurrence, clinical outcome, disease recurrence, clinical outcome, disease recurrence, clinical outcome, disease recurrence, clinical outcome, disease recurrence, clinical outcome, disease recurrence, clinical outcome, disease recurrence, clinical outcome, disease recurrence, clinical outcome, disease recurrence, clinical outcome, disease recurrence, clinical outcome, disease recurrence, clinical outcome, disease recurrence, clinical outcome, disease recurrence, clinical outcome, disease recurrence, clinical outcome, disease recurrence, clinical outcome, disease recurrence, clinical outcome, disease recurrence, clinical outcome, disease recurrence, clinical outcome, disease recurrence, clinical outcome, disease recurrence, clinical outcome, disease recurrence, clinical outcome, disease recurrence, clinical outcome, disease recurrence, clinical outcome, disease recurrence, clinical outcome, disease recurrence, clinical outcome, disease recurrence, clinical outcome, disease recurrence, clinical outcome, disease recurrence, clinical outcome, disease recurrence, clinical outcome, disease recurrence, clinical outcome, disease recurrence, clinical outcome, disease recurrence, clinical outcome, disease recurrence, clinical outcome, disease recurrence, clinical outcome, disease recurrence, clinical outcome, disease recurrence, clinical outcome, disease recurrence, clin"
73,"[/INST]
Prone position training is a behavioral intervention provided to patients with colorectal surgery to prevent postoperative pulmonary complications.
Prone position training is a behavioral intervention provided to patients with colorectal surgery to prevent postoperative pulmonary complications.
Prone position training is a behavioral intervention provided to patients with colorectal surgery to prevent postoperative pulmonary complications.
Prone position training is a behavioral intervention provided to patients with colorectal surgery to prevent postoperative pulmonary complications.
Prone position training is a behavioral intervention provided to patients with colorectal surgery to prevent postoperative pulmonary complications.
Prone position training is a behavioral intervention provided to patients with colorectal surgery to prevent postoperative pulmonary complications.
Prone position training is a behavioral intervention provided to patients with colorectal surgery to prevent postoperative pulmonary complications.
Prone position training is a behavioral intervention provided to patients with colorectal surgery to prevent postoperative pulmonary complications.
Prone position training is a behavioral intervention provided to patients with colorectal surgery to prevent postoperative pulmonary complications.
Prone position training is a behavioral intervention provided to patients with colorectomy.
Prone position training is a behavioral intervention provided to patients undergoing surgery.
Prone position training is a behavioral intervention.
Secondary surgery.
Secondary surgery.
Secondary surgery.
Secondary surgery.
Prone position training is a behavioral surgery.
Second surgery.
Prone surgery.
Second surgery.
Prone surgery.
Second surgery.
Second surgery.
Second surgery.
Second surgery.
Prone surgery.
Second surgery.
Prone surgery.
Second surgery.
Second surgery.
Second surgery.
Second surgery.
Second surgery.
Second surgery.
Second surgery.
Second surgery.
Second surgery.
Second surgery.
Second surgery.
Second surgery.
Second surgery.
Second surgery.
Second surgery.
Second surg"
74,"[/INST]
101 patients with the
1.
1.
1.
1.
1.
1.
2.
2.
1.
2.
1.
1.
1.
2.
1.
1.
2.
1.
2.
2.
1.
1.
2. 1.
2. 1.
1. 1.
2. 1.
1. 1.
2. 1. 1.
1. 1.
1. 1.
1. 1.
1. 1.
1. 1.
1.
2.
1. 1.
1. 1. 1. 1.
1.
2.
2.
1.
1.
2.
2.
1.
1.
1.
1.
1.
1.
1.
1.
1.
1.
1.
The
The
The
The
The
The
The
The
1.
1.
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
The
The
S
This
F
In
This
F
F
F
In
This
This
This
This
This
This
This
This
F
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
Pres
In
P
P
S
F
This
This
This
F
F
F
F
F
This
This
This
F
This
This
This
This
This
This
This
This
This
This
S
S
This
This
This
This
This
S
This
This
This
This
This
This
This
This
This
This
This
S
This
F
F
This
This
This"
75,"[/INST]
Study Design
-----------------
| Primary Purpose: Prevention of frailty syndrome | Secondary Purpose: Improvement of physical function | Time Frame: 6 months |
| Primary Purpose: Prevention of frailty syndrome | Secondary Purpose: Improvement of physical function | Time Frame: 12 months |
| Primary Purpose: Prevention of frailty syndrome | Secondary Purpose: Improvement of physical function | Time Frame: 24 months |
| Primary Purpose: Prevention of frailty syndrome | Secondary Purpose: Improvement of physical function | Time Frame: 12 months |
| Primary Purpose: Prevention of frailty syndrome | Secondary Purpose: Improvement of physical function | Time Frame: 6 months |
| Primary Purpose: Prevention of frailty syndrome | Secondary Purpose: Improvement of physical function | Time Frame: 12 months |
| Primary Purpose: Prevention of frailty syndrome | Secondary Purpose: Improvement of physical function | Time Frame: 6 months |
| Primary Purpose: Prevention of frailty syndrome | Secondary Purpose: Improvement of physical function | Time Frame: 12 months |
| Primary Purpose: Prevention of frailty syndrome | Secondary Purpose: Improvement of physical function | Time Frame: 6 months |
| Primary Purpose: Prevention of frailty syndrome | Secondary Purpose: Improvement of physical function | Time Frame: 12 months |
| Primary Purpose: Prevention of frailty syndrome | Secondary Purpose: Improvement of physical function | Time Frame: 6 months |
| Primary Purpose: Prevention of frailty syndrome | Secondary Purpose: Improvement of physical function | Time Frame: 12 months |
| Primary Purpose: Prevention of frailty syndrome | Secondary Purpose: Improvement of physical function | Time Frame: 6 months |
| Primary Purpose: Prevention of frailty syndrome | Secondary Purpose: Improvement of physical function | Time Frame: 12 months |
| Primary Purpose: Prevention of frailty syndrome | Secondary Purpose: Improvement of physical function | Time Frame: 12 months |"
76,"[/INST]







































































































































































































































































































































































































































777

































8
8
8
8

8
8
8
8

7
8
8
7



7
7
8
8
8
8



8
8
8-"
77,"[/INST]
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This"
78,"[/INST]
Adverse events
Patients in the control group will receive physical therapy and medical treatment.
How is the study designed?
The study will consist of 30 burned patients who will receive resistance exercise and medical treatment.
How is the study designed?
The study will consist of 30 burned patients who will receive resistance exercise and medical treatment.
How is the study designed?
The study will consist of 30 burned patients who will receive resistance exercise and medical treatment.
How is the study designed?
The study will consist of 30 burned patients who will receive resistance exercise and medical treatment.
How is the study designed?
The study will consist of 30 burned patients who will receive resistance exercise and medical treatment.
How is the study designed?
The study will consist of 30 burned patients who will receive resistance exercise and medical treatment.
How is the study designed?
The study will consist of 30 burned patients who will receive resistance exercise and medical treatment.
How is the study designed?
The study will consist of 30 burned patients who will receive resistance exercise and medical treatment.
How is the study designed?
The study will consist of 30 burned patients who will receive resistance exercise and medical treatment.
How is the study designed?
The study will consist of 30 burned patients who will receive resistance exercise and medical treatment.
How is the study designed?
The study will consist of 30 burned patients who will receive resistance exercise and medical treatment.
How is the study designed?
The study will consist of 30 burned patients who will receive resistance exercise and medical treatment.
How is the study designed?
The study will consist of 30 burned patients who will receive resistance exercise and medical treatment.
How is the study designed?
The study will consist of 30 burned patients who will receive resistance exercise and medical treatment.
How is the study designed?
The study will consist of 30 burned patients who will receive resistance exercise and medical treatment.
How is the study designed?
The study will consist of 30 burned patients who will receive resistance exercise and medical treatment.
How is the study designed?
The study will consist of 30 burned patients who will receive resistance exercise and medical treatment.
How is the study designed?
The study will consist of 30"
79,"[/INST]

Other: [/B]"
80,"[/INST]
Other: [/INST]
Adverse events: [/INST]
Patient #1: [/INST]
Intervention: [/INST]
Parameter 1: [/INST]
Parameter 2: [/INST]
Parameter 3: [/INST]
Parameter 4: [/INST]
Parameter 5: [/INST]
Parameter 6: [/INST]
Parameter 7: [/INST]
Parameter 8: [/INST]
Parameter 9: [/INST]
Parameter 10: [/INST]
Parameter 11: [/INST]
Parameter 12: [/INST]
Parameter 13: [/INST]
Parameter 14: [/INST]
Parameter 15: [/INST]
Parameter 16: [/INST]
Parameter 17: [/INST]
Parameter 18: [/INST]
Parameter 19: [/INST]
Parameter 20: [/INST]
Parameter 21: [/INST]
Parameter 22: [/INST]
Parameter 23: [/INST]
Parameter 24: [/INST]
Parameter 25: [/INST]
Parameter 26: [/INST]
Parameter 27: [/INST]
Parameter 28: [/INST]
Parameter 29: [/INST]
Parameter 30: [/INST]
Parameter 31: [/INST]
Parameter 32: [/INST]
Parameter 33: [/INST]
Parameter 34: [/INST]
Parameter 35: [/INST]
Parameter 36: [/INST]
Parameter 37: [/INST]
Parameter 38: [/INST]
Parameter 39: [/INST]
Parameter 40: [/INST]
Parameter 41: [/INST]
Parameter 42: [/INST]
Parameter 43: [/INST]
Parameter 44: [/INST]
Parameter 45: [/INST]
Parameter 46: [/INST
Parameter 47: [/INST
Parameter 48: [/INST
Parameter 49: [/INST"
81,"[/INST]

How is the study designed?
-----------------
Primary Purpose: Cell free DNA in serum, patients with endometriosis, patients with pelvic inflammatory disease, patients with infertility, patients with ovarian failure, patients with premature oocytes, patients with pelvic inflammation, patients with day 1, patients with day 2, patients with ovarian failure, patients with day 3, patients with pelvic inflammation, patients with day 4, patients with day 5, patients with ovarian failure, patients with day 6, patients with day 7, patients with day 8, patients with day 9, patients with day 10, patients with day 11, patients with day 12, patients with day 13, patients with day 14, patients with day 15, patients with day 16, patients with day 17, patients with day 18, patients with day 19, patients with day 20, patients with day 21, patients with day 22, patients with day 23, patients with day 24, patients with day 25, patients with day 26, patients with day 27, patients with day 28, patients with day 29, patients with day 30, patients with day 30, patients with day 31, patients with day 32, patients with day 33, patients with day 34, patients with day 35, patients with day 36, patients with day 37, patients with day 38, patients with day 39, patients with day 40, patients with day 40, patients with day 41, patients with day 42, patients with day 43, patients with day 44, patients with day 44, patients with day 45, patients with day 46, patients with day 47, patients with day 48, patients with day 49, patients with day 50, patients with day 50, patients with day 52, patients with day 51, patients with day 53, patients with day 54, patients with day 54, patients with day 55, patients with day 56, patients with day"
82,"[/INST]

Secondary Outcome Measures
-----------------
| Outcome Measure | Measure Description | Time Frame |
| --- | --- |
| Implant survival | Percentage of number of initially placed overdentures still in place after 10 years | 10 years | 
| Overdenture survival | Peri-implant mucosa condition scored with the Modified Plaque Index, score 0-3, 3 is the worst | at 10 years | 
| Pocket probing depth | Depth of probing in the peri-implant sulcus scored with the Modified Plaque Index, score 0-3, 3 is the worst | at 10 years | 
| Patient satisfaction | Satisfaction of patients scored with a 5-point Likert scale, score 0-3, 3 is the worst | at 10 years | 

Secondary Outcome Measures
-----------------
| Implant survival | Peri-implant mucosa condition scored with the Modified Plaque Index, score 0-3, 3 is the worst | at 10 years | 
| Overdenture survival | Peri-implant mucosa condition scored with the Gingiva Index, score 0-3, 3 is the worst | at 10 years | 
| Patient satisfaction | Satisfaction of patients scored with a 5-point Likert scale, score 0-3, 3 is the worst | at 10 years | 

Secondary Outcome Measures
-----------------
| Implant survival | Peri-implant mucosa condition scored with the Modified Plaque Index, score 0-3, 3 is the worst | at 10 years | 
| Overdenture survival | Peri-implant mucosa condition scored with the Gingiva Index, score 0-3, 3 is the worst | at 10 years | 
| Patient satisfaction | Satisfaction of patients scored with a 5-point Likert scale, score 0-3, 3 is the worst | at 10 years | 

Secondary Outcome Measures
-----------------
| Implant survival | Peri-implant mucosa condition scored with the"
83,[/INST]00000000000000000000000000000-st-st-st-st-st-st-st-be-st-st-be-st-st-st-st-na-O-O-st-st-st-st-st-st-st-st-O-O-O-O-st-st-st-O-0-000000000000000000000-O-h-st-st-st-st-st-O-O-O-O-O-O-O-O-O-O-0-0-0-0-0-0-0-O-O-O-O-O-O-st-0-0-O-O-O-O-O-O-O-O-0-0-st-0-0-0-O-O-O-0-O-0-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O--O-O-O-O-O-O-O-O-O-O--0-0-0-0-0-0-0-0-0-O-O-O-O-0-0-0-0-0-0-0-0-0-O-O-O-O-O-O-0-0-O-0-0-O--------------------------------------------------------------------------------------------------------------------------------0- a a a a-0-0-0-0-
84,"[/INST]

Primary Purpose: Healthy Volunteers will be favorably received by the study physicians. Healthy Volunteers will be defined as those who complete the study and accept the V-CST sessions. This outcome will be assessed at the end of the study.
| Participant Characteristics: [/INST]
Cognitive Impairment: [/INST]
Primary Purpose: Healthy Volunteers will be favorably received by the study physicians. This outcome will be assessed at the end of the study.
| Participant Characteristics: [/INST]
Cognitive Impairment: [/INST]
Secondary Outcome Measure
-----------------
| Participant Characteristics: [/INST]
Cognitive Impairment: [/INST]
Secondary Outcome Measure
-----------------
Cognitive Impairment: [/INST]
Secondary Outcome Measure
-----------------
Cognitive Impairment: [/INST]
Secondary Outcome Measure
Cognitive Impairment: [/INST]
Secondary Outcome Measure
Cognitive Impairment: [/INST]
Secondary Outcome Measure
Cognitive Impairment: [/INST]
Secondary Outcome Measure
Cognitive Impairment: [/INST]
Secondary Outcome Measure
Cognitive Impairment: [/INST]
Secondary Outcome Measure
Cognitive Impairment: [/INST]
Secondary Outcome Measure
Cognitive Impairment: [/INST]
Secondary Outcome Measure
Cognitive Impairment: [/INST]
Secondary Outcome Measure
Cognitive Impairment: [/INST]
Secondary Outcome Measure
Cognitive Impairment: [/INST]
Secondary Outcome Measure
Cognitive Impairment: [/INST]
Secondary Outcome Measure
Cognitive Impairment: [/INST]
Secondary Outcome Measure
Cognitive Impairment: [/INST]
Secondary Outcome Measure
Cognitive Impairment: [/INST]
Secondary Outcome Measure
Cognitive Impairment: [/INST]
Secondary Outcome Measure
C"
85,"[/INST]
|1950s.
|1950s.
|1950s.
|1950s.
|1950s.
|1950s.
GERD.
|1950s.
|1950s.
|1950s.
|1950s.
|1950s.
|1950s.
|1950s.
Conditions.
|1950195000000000000000000001950195.
|1900195019999901950195019501999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999
In.
In.
In.
In.
In.
In
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It.
in
in
It
It
It
It
It
It
It
in
in
in
in
in
in
It
It
It
It
It
It
It
It
It
It
It"
86,"[/INST]

Secondary Outcomes
-----------------
Behavioral: Women who endorse significant DE will complete two weeks of smart-phone self-monitoring to identify target problems and will be sent two self-guided modules of personalized treatment directly to their smart-phones.
Primary Purpose: Men who endorse significant DE will complete two weeks of smart-phone self-monitoring to identify target problems and will be sent two self-guided modules of personalized treatment directly to their smart-phones.
Exclusive to Women: Women who endorse significant DE will complete two weeks of smart-phone self-monitoring to identify target problems and will be sent two self-guided modules of personalized treatment directly to their smart-phones.
Other Specified Diagnoses: Women who endorse significant DE will complete two weeks of smart-phone self-monitoring to identify target problems and will be sent two self-guided modules of personalized treatment directly to their smart-phones.
Study Measures
-----------------
Primary Purpose: Men who endorse significant DE will complete two weeks of smart-phone self-monitoring to identify target problems and will be sent two self-guided modules of personalized treatment directly to their smart-phones.
Secondary Outcome Measures
-----------------
Other Specified Diagnoses: Women who endorse significant DE will complete two weeks of smart-phone self-monitoring to identify target problems and will be sent two self-guided modules of personalized treatment directly to their smart-phones.
Primary Purpose: Women who endorse significant DE will complete two weeks of smart-phone self-monitoring to identify target problems and will be sent two self-guided modules of personalized treatment directly to their smart-phones.
Exclusive to Women: Men who endorse significant DE will complete two weeks of smart-phone self-monitoring to identify target problems and will be sent two self-guided modules of personalized treatment directly to their smart-phones.
Primary Purpose: Women who endorse significant DE will complete two weeks of smart-phone self-monitoring to identify target problems and will be sent two self-guided modules of personalized treatment directly to their smart-phones.
Secondary Outcome Measures
-----------------
Primary Purpose: Women"
87,"[/INST]

Primary Outcome Measure
-----------------
Diagnostic performance of CAD EYE, adenoma detection rate, and histopathological prediction of the endoscopist. Through study completion, an average of 2 years | Comparison of the diagnostic performance of CAD EYE and histopathological prediction of the colonic polyps with the automated system.
Secondary Outcome Measure
-----------------
Diagnostic performance of CAD EYE, adenoma detection rate, and histopathological prediction of the endoscopist. Through study completion, an average of 2 years | Comparison of the diagnostic performance of CAD EYE and histopathological prediction of the colonic polyps with the automated system.

Secondary Outcome Measure
-----------------
Diagnostic performance of CAD EYE, adenoma detection rate, and histopathological prediction of the endoscopist. Through study completion, an average of 2 years | Comparison of the diagnostic performance of CAD EYE and histopathological prediction of the colonic polyps with the automated system.

Secondary Outcome Measure
-----------------
Diagnostic performance of CAD EYE, adenoma detection rate, and histopathological prediction of the endoscopist. Through study completion, an average of 2 years | Comparison of the diagnostic performance of CAD EYE and histopathological prediction of the colonic polyps with the automated system.

Secondary Outcome Measure
-----------------
Diagnostic performance of CAD EYE, adenoma detection rate, and histopathological prediction of the endoscopist. Through study completion, an average of 2 years | Comparison of the diagnostic performance of CAD EYE and histopathological prediction of the colonic polyps with the automated system.

Secondary Outcome Measure
-----------------
Diagnostic performance of CAD EYE, adenoma detection rate, and histopathological prediction of the endoscopist. Through study completion, an average of 2 years | Comparison of the diagnostic performance of CAD EYE and histopathological prediction of the colonic polyps with the automated system.

Secondary Outcome Measure
-----------------
Diagnostic performance of"
88,"[/INST]
| 1940000.
| 194000.
| 19400.
| 19400.
| 194000.
| 194000.
| 194000.
| 194000.
| 1941.
| 194000.
| 1940000.
| 190000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000001
The patients.
The patients.
The patients.
The patients.
The patients.
The patients.
The patients.
The patients.
The patients.
The patients.
The patients.
The patients.
The patients.
The patients.
It.
It.
==
==
==,, it
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
The
The
The
It
It
It
It
It
It"
89,"[/INST]
| Assessment of PK parameter of itepekimab: AUClast | Time to reach EOS (approximately Day 141) | 
| Assessment of PK parameter of itepekimab: tmax | Baseline up to EOS (approximately Day 141) | 
| Assessment of PK parameter of itepekimab: AUClast | Terminal half-life of the serum clearance (approximately Day 141) | 
| Assessment of PK parameter of itepekimab: AUClast | Baseline up to EOS (approximately Day 141) | 
| Assessment of PK parameter of itepekimab: tmax | Time to reach EOS (approximately Day 141) | 
| Assessment of PK parameter of itepekimab: AUClast | Baseline up to EOS (approximately Day 141) | 
| Assessment of PK parameter of itepekimab: tmax | Time to reach EOS (approximately Day 141) | 
| Assessment of PK parameter of itepekimab: AUClast | Baseline up to EOS (approximately Day 141) | 
| Assessment of PK parameter of itepekimab: tmax | Time to reach EOS (approximately Day 141) | 
| Assessment of PK parameter of itepekimab: AUClast | Baseline up to EOS (approximately Day 141) | 
| Assessment of PK parameter of itepekimab: tmax | Time to reach EOS (approximately Day 141) | 
| Assessment of PK parameter of itepekimab: AUClast | Baseline up to EOS (approximately Day 141) | 
| Assessment of PK parameter of itepekimab: tmax | Time to reach EOS (approximately Day 141) | 
| Assessment of PK parameter of itepekimab: AUClast | Baseline up to EOS (approximately Day 141) | 
|"
90,"[/INST]
The study.
The study.
The study.
The subjects.
The subjects.
The subjects.
The subjects.
year.
year.
The study.
The subjects.
The patients.
The patients.
The study.
The study.
The
The
The patients.
The
The study.
The
The
The
The
The
The
The
The
The
The
The
The
The results.
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The   
The   
The
The
The
The
The
The
The
The
The
(year
The
The
(former
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
This
This
The
The
The
The
The
The
This
The
The
This
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The








































s
s
This
g
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
S
S"
91,"[/INST] - - - - -0 - B- - - - - -
-
-
-
-
-
-
-
-
-
- - -
- - - - - - B- B- B- B- D- D- D- B- B- B- B- B- B- B- B- B- B- B- B- B- B- B- B- - - - - B- B- B- B- B- B-
 B-
- B- B- B- B- B- B- B- B- B- - - - - - - - - - - B- B- B- B- B- B- B- B- B- B- - - - - - - - - - B- B- B- B- B- B- B- B- B- B- B- B- - - - - - - - - - -      B-  B- - - - - - - - - - - - - - - - - - - - - -         - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - B- B- - - - - - - - B- - - - B- B- B- B- B- B- B- B- B- B- B- B- B- B- B- - B- B-
- - - - - - - - -
-
-
-
-
-
-
- - - - - - - - - -
-
-
-
-
-
-
-"
92,"[/INST]

Cancer patients with venous thromboembolism or atrial fibrillation
Secondary Prevention / Intervention
Apixaban and rivaroxaban are both anticoagulants studied in cancer patients with venous thromboembolism or atrial fibrillation. This study aims to describe important differences between them.
Apixaban is a factor X inhibitor that is used in the treatment of venous thromboembolism and atrial fibrillation.
Rivaroxaban is a factor Y inhibitor that is used in the treatment of cancer.
Cancer patients with venous thromboembolism or atrial fibrillation are eligible for this study.
Inclusion Criteria: Age 18 years, able to provide written informed consent.
Exclusion Criteria: Life expectancy <3 months Monitoring of cancer patients receiving rivaroxaban or apixaban
Intervention / Treatment
Secondary Prevention / Intervention Strategy Cancer patients with venous thromboembolism or atrial fibrillation
Apixaban is a factor Y inhibitor that is used in the treatment of cancer patients with venous thromboembolism or atrial fibrillation.
Monitoring of cancer patients receiving rivaroxaban is ongoing.
Data related to the safety of apixaban is limited.
Cancer patients with venous thromboembolism or atrial fibrillation are eligible for this study.
Apixaban is a factor Y inhibitor that is used in the treatment of cancer patients with venous thromboembolism or atrial fibrillation.
Monitoring of cancer patients receiving rivaroxaban is ongoing.
Data related to the safety of apixaban is limited.
Cancer patients with venous thromboembolism or atrial fibrillation are eligible for this study.
Secondary Prevention / Intervention Cancer patients with venous thromboembolism or atrial fibrillation are eligible for this study.
Data related to the safety of apixaban is limited.
Monitoring of cancer patients receiving rivaroxaban is ongoing.
Cancer patients with venous thromboembolism or atrial"
93,"[/INST]
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
O
A
A"
94,"[/INST]
8
8
8
8
8
8
8
8
8
A
A
A
A
A
A
A
A
A
A
A
m
m
m
8
8
8
8
8
A
A
A
A
A
A
A
A
A
A
A
A
A
A-
A-
A-h-
8-
8
8
8
8
8
8
8
8-
8
8
8
8
8-
8-
8-
8-
A-
A-
O-
8-
8-
8-
8-
8-
8-
8-
8-
8-
8-
-
-
-
-
3-
8-
-h-h-
-
-
-
-h-
-
-
-
-
-
-
-
-
-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-8-8-8-h-8-8-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-h-h-
-h-
-
-
-h-h-h-h-
-
-
-
-
-
-
-
-
O
-h-
-
-
-
-
-
-
-
-
-
-
ities
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-























-
-
-
istic
istic
istic
istic
istic
istic
istic"
95,"[/INST]
|1 year|1 year|1 year|1 year|1 year|1|1 year old|1|1 year old|1 year old|1 year old|1 year old|1 year old|1 year old|1 year old|1 year old|1 year old.
|1 year old.
|1 year old|1 year old|1 year old|1 year old|1 year old|1 old|1 year old.
|1 year old.
Stroke.
Stroke.|1 year old.
|1 year old.
|1 year old|1 year old patients|1 year old|1|1|1000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000001.
The increase.
The increase.
The increase.
The000000000000001010101000101010101010101111110101010000000101011111116
The.
This.
This.
This.
This00000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
This
01
0000000000000000000000000000000"
96,"[/INST]
Terms related to the study. Non-invasive
| Evaluate the acceptance of dysmia.
| 15 minutes after the two interventions.
| 15 minutes after the study.
Terms related to the study.
| 15 minutes after the two interventions.
| 15 minutes after the two interventions.
| 15 minutes after the two interventions.| 15 minutes after the two interventions.| 15 minutes after the two interventions.|15 minutes after the two interventions.|15 minutes after the two interventions.|15 minutes after the two interventions.|15 minutes after the two interventions.|15 minutes after the two interventions.|15 minutes after the two interventions.|15 minutes after the two interventions.|15 minutes after the two interventions.|15 minutes after the two interventions.|15 minutes after the two interventions.|15 minutes after the two interventions.|15 minutes after the two interventions.|15 minutes after the two interventions.|15.
|15.
|15.
Sympt
Sympt
Sympt
Sympt
Sympt
Sympt
Sympt
Sympt
Sympt
Sympt
Sympt
Sympt
Sympt
Sympt
Symmeters.
Sympt
Sympt
Sympt
Sympt
Sympt
Symple.
Sym
Sympath.
Sym.
Sympt
Sym
Symmet
Sym
Sym
Symmet
Symmet
Sym.
Sym.
Sym.
Sym.
Sym.
Sym.
The sympt
The sympt
The treatment.
The symptoms.
The symptoms.
The symptoms.
The sympt
The sympt
The.
The.
The disease.
The disease.
The disease.
The sympt
The.
The.
The.
The treatment.
The treatment.
The patient.
The disease.
The, it.
The.
The process.
The.
The,,
The,,
The,,
The,.
The.
The.
In.
The|
This."
97,"[/INST]
Primary Outcome Measure
| Rate of broad-spectrum antibiotic dispensing as a function of the number of selective antibiotic susceptibility testings | 5 days | 
| GP characteristics: demographics (age, gender, diabetes, pregnancy) | Impact of targeted antibiotic susceptibility testing compared to of a standard antibiotic susceptibility test as a function of the patient characteristics | 5 days | 
| E. coli antimicrobial susceptibility profiles | Impact of targeted antibiotic susceptibility testing compared to of a standard antibiotic susceptibility test as a function of the patient characteristics | 5 days | 
| Rate of broad-spectrum antibiotic dispensing as a function of the number of selective antibiotic susceptibility testings | 5 days | 
| GP characteristics: demographics (age, gender, diabetes) | Impact of targeted antibiotic susceptibility testing compared to of a standard antibiotic susceptibility test as a function of the patient characteristics | 5 days | 
| E. coli antimicrobial susceptibility profiles | Impact of targeted antibiotic susceptibility testing compared to of a standard antibiotic susceptibility test as a function of the patient characteristics | 5 days | 
| Rate of broad-spectrum antibiotic dispensing as a function of the number of selective antibiotic susceptibility testings | 5 days | 
| GP characteristics: demographics (age, gender, diabetes) | Impact of targeted antibiotic susceptibility testing compared to of a standard antibiotic susceptibility testings as a function of the patient characteristics | 5 days | 
| Rate of broad-spectrum antibiotic susceptibility testings as a function of the number of selective antibiotic susceptibility testings as a function of the patient characteristics | 5 days | 
| E. coli antimobiles characteristics | 5 days | 5 days | 5 days
| 5 days | 5 days
| 5 days
| 5 days
| 5 days
| 5"
98,"[/INST]
The goal. The clinical psychiatric neuros.
The clinical symptoms in the first to know that the cause about 0.
The clinical psychiatric neuros. It is the reason. It has been proven in the clinical trials. It is the reason. It is the most effective treatment.
The clinical psychiatric symptoms.
The clinical psychiatric symptoms. It is the reason. It is the reason. It has been diagnast
The clinical psychological symptoms. It is the most effective treatment. It is the most. It. It. It. It. It. It. It. It's clinical syndrome. It. It. It. It.
The treatment. It's clinical disease. It is the treatment. It. It. It. It. It.
The.
The patients.
It.
It's.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It's.
It's.
It.
It.
It.
It.
It.
It
It's
it.
It.
It.
It.
It.
It
It
It
The.
The.
This.
This.
This.
This
This
This
This
This
This
It
This
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
it
It
It
be
be
be
be
be
be
/>
/>
/>
/>
/>
/>
/>
be
be
be
be
be
be
be
be
be
be
be
be
be
be
be
be
be
be
g
be
be
be
be
be
be
be
be
be
be
be
be
be
a
a
be
be
be
be
be"
99,"[/INST]

Adverse Events
-----------------
| Expected number of deaths or serious adverse events per 1000 patients | at least 10% of patients will experience a serious adverse event | no specific estimates of harms provided |
| Expected weight change per 1000 patients | at least 5% of patients will experience a serious adverse event |
| Expected to be a serious adverse event per 1000 patients | at least 10% of patients will experience a serious adverse event |
| at least 5% of patients will experience a serious adverse event |
| Expected to be a serious adverse event per 1000 patients | at least 10% of patients will experience a serious adverse event |
| at least 10% of patients will experience a serious adverse event |
| Expected to be a serious adverse event per 1000 patients | at least 10% of patients will experience a serious adverse event |
| at least 10% of patients will experience a serious adverse event |
| at least 10% of patients will experience a serious adverse event |
| at least 10% of patients will experience a serious adverse event |
| at least 10% of patients will experience a serious adverse event |
| at least 10% of patients will experience a serious adverse event |
| at least 10% of patients will experience a serious adverse event |
| at least 10% of patients will experience a serious adverse event |
| at least 10% of patients will experience a serious adverse event |
| at least 10% of patients will experience a serious adverse event |
| at least 10% of patients will experience a serious adverse event |
| at least 10% of patients will experience a serious adverse event |
| at least 10% of patients will experience a serious adverse event |
| at least 10% of patients will experience a serious adverse event |
| at least 10% of patients will experience a serious adverse event |
| at least 10% of patients will experience a serious adverse event |
| at least 10% of patients will experience a serious adverse event |
|"
100,[/INST]-st-st-st-st-M-M-st-M-c-M-M-M-c-8-8-c-M-M-M-M-M-M-M-M-c-c-M-st-M-M-M-M-M-st-m-st-st-st-m-st-M-st-st-M-M-M-M-M-M-M-M-M-M-M-M-M-M-st-st-M-st-st-st-st-st-st-st-st-a-a-a-M-M-M-M-a-M-M-M-M-M-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-p-a-p-p-p-st-st-st-p-p-p-p-p-a-st-st-st-st-st-st-st-st-st-M-M-st-M-M-M-M-M-M-M-M-M-st-st-st-st-st-a-st-M-st-a-a-st-M-M-M-st-st-st-M-a-a-st-st-st-st-st-st-a-a-a-a-M-a-st-st-st-st-m-m-m-m-m-m-st-a-a-a-a-a-a-a-a-a-m-m-st-st-st-st-st-st-st-M-M-M-M-M-M-M-M-M-M-M-M-M-M-M-M-M-M-M-M-M-M-M-M-M-M-M-M-M-M-M-M-M-M-M-M-M-M-M-M-M---M-M-M-M-M-M-M-M-M-M-M-M-M-M-M-M-M-M-M-M-M
101,"[/INST]
Other: [/INST]
Accepted: [/INST]
Primary Purpose: To evaluate the change in pain intensity over time Secondary Purpose: To express the acceptance of the investigator after treatment Tertiary Purpose: To evaluate the change in symptoms over time
Other: [/INST]
Secondary Outcome Measure
Accepted: [/INST]
Primary Purpose: To evaluate the change in pain intensity over time Secondary Purpose: To express the acceptance of the investigator after treatment Tertiary Purpose: To evaluate the change in symptoms over time
Other: [/INST]
Primary Purpose: To evaluate the change in pain intensity over time Secondary Purpose: To express the acceptance of the investigator after treatment Tertiary Purpose: To evaluate the change in symptoms over time
Accepted: [/INST]
Primary Purpose: To evaluate the change in pain intensity over time Secondary Purpose: To express the acceptance of the investigator after treatment Tertiary Purpose: To evaluate the change in symptoms over time
Other: [/INST]
Primary Purpose: To evaluate the change in pain intensity over time Secondary Purpose: To express the acceptance of the investigator after treatment Tertiary Purpose: To evaluate the change in symptoms over time
Accepted: [/INST]
Primary Purpose: To evaluate the change in pain intensity over time Secondary Purpose: To express the acceptance of the investigator after treatment Tertiary Purpose: To evaluate the change in symptoms over time
Other: [/INST]
Primary Purpose: To evaluate the change in pain intensity over time Secondary Purpose: To express the acceptance of the investigator after treatment Tertiary Purpose: To evaluate the change in symptoms over time
Accepted: [/INST]
Primary Purpose: To evaluate the change in pain intensity over time Secondary Purpose: To express the acceptance of the investigator after treatment Tertiary Purpose: To evaluate the change in symptoms over time
Other: [/INST]
Primary Purpose: To evaluate the change in pain intensity over time Secondary Purpose: To express the acceptance of the investigator after treatment Tertiary Purpose: To evaluate the change in symptoms over time
Accepted: [/INST]"
102,"[/INST]
Other: [/INST]
Adverse events, serious or unexpected events, that were reported in 13-14 year old females who received their first dose of domestic bivalent HPV vaccine or imported HPV vaccine, and 36 months (window period  1 month) after the last dose of vaccination.
Serious or unexpected adverse events, that were reported in 13-14 year old females who received their first dose of domestic bivalent HPV vaccine or imported HPV vaccine, and 36 months (window period  1 month) after the last dose of vaccination.
Participants: 13-14 year old females who received their first dose of domestic bivalent HPV vaccine or imported HPV vaccine, and 36 months (window period  1 month) after the last dose of vaccination.
Primary Outcome Measures
-----------------
Serious or unexpected adverse events, that were reported in 13-14 year old females who received their first dose of domestic bivalent HPV vaccine or imported HPV vaccine, and 36 months (window period  1 month) after the last dose of vaccination.
Secondary Outcome Measures: [/INST]
Serious or unexpected adverse events, that were reported in 13-14 year old females who received their first dose of domestic bivalent HPV vaccine or imported HPV vaccine, and 36 months (window period  1 month) after the last dose of vaccination.
Other: [/INST]
Secondary Outcome Measures: [/INST]
Serious or unexpected adverse events, that were reported in 13-14 year old females who received their first dose of domestic bivalent HPV vaccine or imported HPV vaccine, and 36 months (window period  1 month after the last dose of vaccine.
Secondary Outcome Measures: [/INST and 13-14 year old females who received their first dose of vaccine or imported HPV vaccine, and 18-14"
